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ABSTRACT
Although conventional risk factors such as hypertension, diabetes, smoking and 
dyslipidaemia are all established risk factors for cardiovascular disease, they do not 
explain the total risk. Arterial stiffness has emerged as a major independent risk factor 
for cardiovascular disease and measurement of arterial stiffness in clinical practice 
should improve the diagnosis and management of patients with cardiovascular 
disease.
Study 7, compared 3 methods of assessing arterial stiffness and found that: each 
method of assessment was comparable to the other and that reproducibility was 
similar throughout the systems. Within-observer variation was also very low, 
suggesting that high quality and accurate recordings of arterial stiffness measurements 
were obtained.
Study 2. Since there are conflicting data associated with arterial stiffness and type-2 
diabetes, study 2a and 2b therefore assessed arterial stiffness, using pulse wave 
analysis and pulse wave velocity and found there to be increased arterial stiffness in a 
group of type-2 diabetics compared to healthy controls.
Study 2c and 2d. Since there are also ethnic variations in cardiovascular risk, the 
second study also investigated differences in arterial stiffness between South Asians 
and Caucasians, with and without diabetes and found that South Asians had 
significantly lower arterial stiffness in the femoral and aortic vascular bed compared 
to the Caucasians, whilst having higher arterial stiffness in the radial vascular bed. 
Study 3. Although diabetes is known to increase arterial stiffness, the effect of pre­
diabetes (impaired fasting glucose) on arterial stiffness is unclear. The effect of 
impaired fasting glucose on arterial stiffness has therefore been investigated in the 
third study and the findings demonstrate that individuals with impaired fasting
III
glucose have increased arterial stiffness compared to individuals with normal fasting 
glucose. Similar findings were observed when comparing diabetics and individuals 
with normoglycaemia.
Study 4. Finally, therapeutic intervention targeted at increased arterial stiffness should 
be of benefit in reducing the prevalence of cardiovascular disease. The fourth study 
has therefore also examined the effect of regular aerobic exercise on arterial stiffness 
and found that in older individuals, arterial stiffness was significantly lower in a group 
of individuals who exercised regularly compared to sedentary controls. Therefore, 
suggesting the potential benefit of aerobic exercise as a non-pharmacological 
intervention to decrease arterial stiffness and cardiovascular disease.
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Chapter I. Introduction to Arterial Stiffness
INTRODUCTION 
1.1 Historical perspectives
1.1.1 History o f arterial stiffness
The ancient Greeks believed that the blood vessels were in fact air tubes used for 
transporting air through the body. The word “Artery”, originating from the Greek 
words of aer and terein, meaning air-duct. This was the general consensus up until the 
early 17th century when Harvey published a book entitled “An Anatomical Essay on 
the Movement of the Heart and Blood in Animals”, in which he described the 
circulation of the blood vessels and the heart 1 and laid the foundations of modem 
cardiovascular medicine. However, the blood vessels themselves were still thought to 
be simple conduits with the sole function of conveying blood from the heart to the 
vital organs and back again.
Therefore, despite Harveys’ seminal work, research in cardiovascular medicine was 
slow to progress and it was not until one hundred years later that Reverend Stephen 
Hales recorded the arterial pressure in a horse. Using only a water manometer at the 
carotid artery, arterial pressure was recorded along with simultaneously demonstrating
a
the effects of exsanguinations . The height of the water in the manometer equated to 
the arterial pressure being the first early equivalent of the mercury column 
sphygmomanometer used today.
Hales further compared the elastic arterial system to that of a contemporary fire 
engine. Termed the “Windkessel” model, Hales described the air-filled chamber as the 
buffer that converts pulsatile flow at the input to the steady state flow at the nozzle.
1
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However, this model proved too simplistic, as it did not totally consider wave travel 
and reflection.
Indeed, all the early studies measured pressure and it was not until much later that 
flow was measured. The French physicist Poiseuille, investigated the factors 
responsible for the resistance to flow in tubes of capillary dimensions 3 which lead to 
the identification of pressure fluctuations during each heart beat. These and the 
findings of others encouraged early researchers to search for more objective and 
sensitive methods of assessing the arterial pulse.
Eventually Marey developed a series of devices which he termed sphygmographs, 
essentially consisting of a base plate over a radial artery connected to a smoked drum 
driven by clockwork on which the fluctuations in the arterial pulse were recorded 4. 
Figure 1.1. Sphygmographs developed by Marey (taken from O’Rourke. The 
arterial pulse. 1992)5
2
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Such devises were further refined over the ensuing years. However, it was Frederic
Guy’s, the effects of renal disease on arterial pressure had just been noted by Richard
with Bright’s disease and compared them to healthy subjects. He was able to correctly 
identify the characteristic hypertensive pressure pulse waveform with a late systolic 
peak and little or no diastolic fluctuation. Using the sphygmograph, Mahomed was 
also able to study the pre-albuminuric stages of Bright’s disease. Mahomed therefore 
promoted the use of pulse waveforms in clinical practice.
Mahomed was also able to show differences in waveforms between old and young 
subjects (Figure 1.2). Although at the time he himself failed to fully appreciate the 
relationship between changes in the arterial wave and arterial stiffness.
Figure 1.2. Difference in pulse waves recorded by Fredrick Akbar Mahomed,
Akbar Mahomed, when a medical student at Guy’s hospital London who was to make 
one of the most significant contributions 6. At the time Mahomed was working at
Bright 1. Mahomed used the sphygmograph to record pulse waveforms from patients
1874.
(A) Illustrates the first waveforms measured in young individuals.
(B) Illustrates the different waveforms measured in older individuals.
3
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“The pulse ranks the first among our guides; no surgeon can despise its counsel, no
physician can shut his ear to its appeal”
(Frederick Akbar Mahomed 1874) taken from 5.
Early physicians continued to regard stiffening of the arteries as an inevitable 
consequence of aging, and its clinical significance was not fully appreciated by many. 
Nevertheless, a physiologist by the name of C.S. Roy, in the early 1880’s, suggested 
that with increasing age, the stiffness of the arteries changed, and that this might have 
a consequence for the health of the individual. He stated that:
“Only in the case of young children do we find that the elasticity of the arteries is so 
perfectly adapted to the requirements of the organism as it is in the case of the lower
animals”8
A major problem for Mahomed was that although he was able to identify clear 
qualitative differences in the arterial waveform between health and disease he was 
unable to quantify them. This precluded the widespread introduction of the 
sphygmograph into clinical practice and subsequent work by Riva-Rocci (1896) and 
Korotkov (1905) led to the introduction of the forerunner of the modem 
sphygmomanometer. However, the sphygmomanometer only provided information as 
to the extremes of blood pressure, systolic and diastolic and all the information 
contained in the pressure waveforms of Mahomed was ignored.
Despite such reservations, the sphygmomanometer superseded the sphygmograph and 
was introduced into widespread clinical practice.
4
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However, a number of researchers remained interested in the arterial waveform and 
subsequently a number of devices to record the arterial waveform were developed that 
unlike the original sphygmographs, were able to provide quantitative data. One such 
device the vasculograph 9 was used to assess the effect of age, exercise, hypertension 
and drugs on the arterial waveform in the 1950s and 1960s.
Furthermore, the widespread introduction of the sphygmomanometer was 
accompanied by clinicians focusing on diastolic pressure as being of major 
importance as the rise in systolic pressure was regarded as part of the natural ageing 
process and not as predictive of CV risk. Indeed many early physicians regarded a 
high systolic pressure as a good feature being representative of “cardiac strength”. 
Subsequently this has been shown to be misguided, as age related arterial stiffening 
has been clearly demonstrated to be a major risk factor for cardiovascular events. 
Indeed, pulse pressure (the difference between systolic and diastolic pressure) has 
been shown in older individuals to be a better predictor of CV events than either 
systolic or diastolic pressure10' 13. Furthermore, with the increased longevity of many 
modem societies isolated systolic hypertension (ISH), the result of age related arterial 
stiffening is increasing exponentially, such that individuals who are normotensive at 
age 50yrs have a lifetime risk of developing hypertension of 90%.
Modem appreciation of the deleterious impact of arterial stiffening on vascular 
haemodynamics and ventricular-vascular interactions, coupled with improved 
technology has lead to the development of a number of devices for measuring arterial 
stiffness in clinical practice. These developments have enabled clinicians and 
researchers to improve diagnosis, risk stratification and therapeutic management of 
patients with premature arterial stiffening, due to CV risk factors. Indeed, arterial
5
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stiffness has emerged many years after Mahomed’s original experiments as a major 
independent risk factor for CV disease in the 21st century.
1.2 Definition and measurement of arterial stiffness
1.2.1 Arterial stiffness
“In extreme old age, the arteries themselves, the grand instrument o f  the circulation, 
the continual apposition o f  earth, become hard, and as it were bony, till, having lost 
the power o f  contracting themselves they can no longer propel the blood, even 
through the largest channels, in consequence o f  which death naturally ensues. ”
(John Wesley, 1703-1791)
Although John Wesley appreciated the importance and predictive value of arterial 
stiffness in terms of mortality there was no way of defining or measuring arterial 
stiffness available. The generic term “arterial stiffness” in simple terms defines how 
elastic, stiff, distensible or compliant an artery is. This term will be used throughout 
the thesis.
Terms used to describe the properties of the vessel walls are defined in Table 1.1 
Important indices and methods of assessment include compliance, elasticity, 
distensibility and vascular impedance. However, interpretation of these indices 
remains complicated since many are dependent on blood pressure. Thus stiffness 
index may be more useful clinically as it is less dependent on blood pressure. In 
assessment of vascular impedance 14 the circulatory system is compared to an 
electrical circuit. Impedance then describes the relationship between forces acting in
6
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the circulation to the motion of the blood. However, the introduction of impedance 
measurements into clinical practice has been limited by the necessity to measure 
pressure and flow simultaneously at a fixed point in the circulation. Therefore 
characteristic impedance is probably the most useful clinically, as it relates pressure 
and flow. However, this makes an assumption that there is no pressure wave reflection 
within the system which is an over simplification. Input impedance on the other hand 
describes the impedance of the vascular bed as a whole and is therefore influenced by 
wave reflection.
7
Table 1.1. Methods used in the determination of arterial stiffness. (Modified from Woodman et al, 2003)
T erm Definition M ethods of 
Assessm ent
Elastic Modulus Pressure change required for a theoretical 100% stretch from resting diameter:
(AP.D)/AD (mmHg)
MRI
Ultrasound
Young’s Elastic 
Modulus 'F
Elastic modulus per unit area: (AP.D)/AD.h2(mmHg/cm2) MRI
Ultrasound
Arterial Distensibility Relative change in diameter (or area) for a given pressure change; inverse of elastic
modulus: AD/(AP.D) (mmHg'1)
MRI
Ultrasound
Arterial Compliance Absolute diameter (or area) change for a given pressure step:
AD/AP (mmHg) or (cm2/mmHg)
MRI
Ultrasound
Pulse Wave Velocity Velocity of travel of a pulse along a length of the artery: Distance/At (m/s) Pressure waveform 
Volume waveform 
MRI, Ultrasound
Augmentation Index Difference between second and first systolic peaks as a percentage o f the pulse pressure:
((P2-P1)/PP) * 100
Pressure Waveform
Stiffness Index (P)'P Ratio o f logarithm (systolic/diastolic pressures) to (relative changes in diameter):
P= In(Ps/Pd) /  (Ds-Dd)/Dd
Ultrasound
Capacitative compliance Relationship between pressure change and volume change in the arteries during the 
exponential component of diastolic pressure decay: AV/AP(cm3/mmHg)
Pressure waveform
Oscillatory Compliance Relationship between oscillating pressure change and oscillating volume change around the 
exponential pressure decay during diastole: AV/AP(cm3/mmHg)
Pressure waveform
P: pressure, D: diameter, V: volume, h: wall thickness, t: time, v: velocity, s: systolic, d: diastolic, *P: a/5 0  requires pressure measurements.
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1.2.2 Measurement o f arterial stiffness
There are several methods in use for the measurement of arterial stiffness. Some 
methods are more widely used than others, due to their easy operational procedure, 
relative low cost and mobility. However, whilst some techniques give information on 
systemic arterial stiffness, others only give information on local stiffness of the vessel 
being studied. It is therefore important that different techniques are not used 
interchangeably when comparing data.
In this thesis, pulse wave analysis (PWA) and pulse wave velocity (PWV) are used to 
assess arterial stiffness.
1.2.2.1 PWA
To better understand the technique of PWA it is vital to appreciate that the arterial 
pressure wave form wherever it is measured in the arterial tree will be a composite of 
a forward going pressure wave (produced by ventricular ejection) and a reflected 
wave. The reflected wave travels back from the periphery and sites of reflection, 
usually arterial bifurcations or sites of impedance mismatch. Therefore, the arterial 
waveform varies along the arterial tree 15. The velocity at which the wave will travel 
along the arterial wall is dependant on how stiff the artery is. The greater the arterial 
stiffness of the vessel, the higher the pulse wave velocity. The more elastic the artery 
is, the slower the pressure wave will travel along the arterial tree. Furthermore, the 
slower the reflected wave will return to the aortic root. If the reflected wave returns 
slowly, the wave will reach the heart during diastole. Thus, augmenting diastolic 
pressure and increasing coronary perfusion. In the case of stiff arteries, the reflected
9
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wave will return earlier to the aortic root, thus augmenting central systolic pressure 
with a consequent decrease in diastolic pressure. This early return of the reflected 
wave can also lead to left ventricular hypertrophy (LVH).
Non-invasive analysis of central arterial wave forms has been made possible with the 
development of the SphygmoCor system by O’Rourke and colleagues 16. Using the 
SphygmoCor system, peripheral pressure waveforms are recorded non-invasively with 
a high fidelity applanation tonometer 17. The tonometer with a Millar 
micromanometer at its tip, is used to flatten but not occlude a peripheral artery (radial, 
carotid). Circumferential pressures are thus equalised and accurate recording of the 
pressure waveform is obtained. The peripheral waveform is then transformed into the 
corresponding central arterial waveform, using Fourier analysis, and a validated 
generalised transfer function based on data obtained from invasive measurements 18,19. 
Augmentaion index (AIx), a measure of systemic arterial stiffness can then be 
calculated as the difference between the second and first systolic peaks expressed as a 
percentage of the pulse pressure (Figure 1.3), and derived central pressure16. In 
addition, by gating the measurements to the R wave of an ECG, and recording at two 
sites, aortic (carotid to femoral) PWV can also be measured.
10
Chapter L Introduction to Arterial Stiffness
Figure 13. A typical aortic pressure waveform constructed by the SphygmoCor 
software.
P2
Incisura
PP
Tf: Foot o f  the forward travelling+wave, Tr: time difference between the foot o f the 
wave and the point at which the reflected wave has an effect (the inflection point), PI 
& P2: first and second systolic peaks, PP: pulse pressure.
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1.2.2.2 PWV
Pulse wave velocity describes the speed at which the pressure wave generated by left 
ventricular contraction travels down the arterial tree from the aorta to the site of 
measurement in the peripheral vasculature. It is calculated by measuring the time 
taken for the arterial pressure wave to travel between two points a measured distance 
apart, and thus requires measurements to be made at two different sites within the 
arterial system. This can be achieved either by simultaneous measurement or by 
gating recordings to a fixed point in the cardiac cycle, often the R wave on the ECG. 
It is important to have a good reference point on the recorded waveforms and the 
majority of systems employ a foot-to-foot methodology, as this has been shown to 
avoid confounding by wave reflection within the system.
PWV can be measured by a variety of methods, either invasive or non-invasive, and 
can be applied to either flow or pressure waves. PWV provides information on the 
distensibility of the local vessel being studied, rather than on systemic arterial 
stiffness. Distensibility being inversely related to stiffness. The relationship between 
PWV and distensibility is defined in the Bramwell Hill equation as:
PWV= V( 1/Dp)
Where D = distensibility and p = density of blood.
12
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Other methods o f assessing arterial stiffness
1.2.2.3 MRI
Magnetic resonance imaging (MRI) is being increasingly used in modem clinical 
practice and can be adapted to measure arterial distensibility non-invasively. The 
majority of studies to date have measured disensibility in the aorta. This is important, 
as aortic distensibility is influenced by pressure within the aorta and this will be 
different from pressure in the brachial artery due to the phenomenon of pressure wave 
amplification. Since many of the MRI studies published to date have used brachial 
artery pressure to calculate distensibility they remain difficult to interpret. In addition, 
MRI is expensive, immobile, time consuming, needs well-trained staff and can only 
be applied to large arteries. For this reason, its place in clinical practice remains 
speculative.
1.2.2.4 Ultrasound
Ultrasound can also be used in assessment of arterial stiffness (compliance and 
distensibility). Using ultrasound is limited to the larger and more accessible arteries. 
Therefore this technique has been used to assess compliance or distensibility at the 
carotid, brachial, abdominal aorta and femoral artery sites.
Although ultrasound has the advantage of being non-invasive, imaging equipment is 
expensive and not very portable. The technique is very operator dependent as it is 
highly reliant on accurate determination of vessel wall diameters.
1.2.2.5 Photoplethysmography
The technique of Photoplethysmography (digital pulse contour analysis) is another 
method of assessing arterial stiffness. This technique utilises the transmission of
13
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infrared light through the finger to detect changes in flow and produce a volume 
waveform. Developers of the system have devised a reproducible parameter termed 
“stiffness index” (SI), by measuring the time delay between direct and reflected waves
onin the digital volume pulse . One disadvantage of this method is that it uses height to 
estimate arterial path length. However, SI has demonstrated to be significantly 
correlated to the “gold standard” method of assessing arterial stiffness, CF PWV. 
Therefore, it may be used as a valid surrogate measure for aortic PWV.
1.3 Variations in arterial stiffness throughout the arterial tree
Arteries vary in size from the largest most elastic section of the arterial tree known as 
the aorta to the smaller branched muscular arteries of the arterial tree. Arterial 
diameters range from a few centimetres in the aorta to less than 200pm in the tiny 
resistance vessels known as arterioles. Structural properties of the vessels vary from 
the conduit arteries to the arterioles and will thus influence local PWV and elastic 
modulus (Figure 1.4). The aorta comprises of predominantly elastin and collagen 
fibres along with smooth muscle, whilst the iliac and femoral arteries are more 
muscular. Changes in the composition of the arterial wall, predominantly the balance 
between elastin and collagen, will effect the pressure flow relationships at various 
points in the arterial tree (Figure 1.5).
Structural differences, as the pulse travels from the elastic central arteries to the more 
muscular peripheral arteries have an important role to play in wave reflection. As 
portrayed in Figure 1.4, pulse wave velocity increases as the pressure wave travels 
along increasingly muscular arteries as it moves down the arterial tree. This increased 
PWV together with branching of the aorta and narrowing of the lumen, creates an
14
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impedance mismatch, resulting in partial reflection of the forward travelling pressure
y  i
waveform . An increased number of these sites of impedance mismatch can increase 
the velocity of the reflected wave, resulting in augmented central pressure.
Figure 1.4. Variations in arterial stiffness throughout the arterial tree. Taken
from 21
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As the aorta and large vessels stiffen with age impedance mismatch decreases, leading
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to less wave reflection. This is supported by the finding that AIx plateaus and in
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some cases decreases after age 55yrs. This may be an explanation for the link 
between arterial stiffness and microvascular disease in that the decrease in wave 
reflection may thus expose the microvasculature to an increased direct pulsatile load. 
This is especially true for high flow, low pressure, circulations such as the brain and 
the kidney. Indeed, a recent study showed that PP, a surrogate for arterial stiffness 
was the best correlate of deterioration in renal function in a group of hypertensive 
subjects with normal renal function at baseline 24
Figure 1.5. Haemodynamic and structural differences observed between the 
different sections of the vasculature.
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1.4 Haemodvnamic consequences of arterial stiffness
1,4.1 Increased central blood pressure
Arterial stiffening and enhanced wave reflections from the periphery cause systolic 
blood pressure to rise and diastolic pressure to fall in the central arteries. This results 
in a widening of the central pulse pressure. Moreover, it is the pressure in the central, 
not peripheral arteries to which the major organs are exposed. Since there are now a 
range of techniques with which to assess central blood pressure including the 
SphymoCor system as used in the current studies, there has been increased interest in 
central blood pressure in the pathogenesis of cardiovascular disease. This interest in 
central blood pressure has been re-enforced by a recent large population based study 
demonstrating that central aortic blood pressure was a better predictor of CV outcome 
than blood pressure measured conventionally in the brachial artery25.
Pulse pressure in the central arteries is influenced by three major haemodynamic 
mechanisms: stroke volume, aortic stiffness, and wave reflections. The large elastic 
arteries normally buffer the cyclical changes in pressure which occur during each 
cardiac cycle. However, as elastic arteries become stiffer, due to ageing or disease, 
this buffering capacity is reduced and central systolic pressure increases. The rise in 
systolic pressure is augmented further by a faster return of reflected pressure waves 
from the periphery. In addition, diastolic blood pressure falls, because stiffened 
arteries can no longer recoil as effectively. Although a marker of increased arterial 
stiffness, these changes in central pulse pressure may also promote cardiovascular 
disease.
The function of the heart is to pump blood through the arterial system to the organs 
and tissues in an amount sufficient to meet their metabolic needs at rest and during
17
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periods of stress. The amount of oxygen used by the left ventricle to produce the 
cardiac output is dependent not only on the contractile properties of the myocardium, 
but also on the physical properties of the large arteries and resistance vessels. As such, 
it is the central, not peripheral blood pressure, which constitutes the afterload placed 
on the ventricle during cardiac ejection.
If the heart is ideally matched to its afterload, there is optimal coupling between the 
ventricle and the vascular system and cardiac efficiency is high. However, any 
increase in central systolic blood pressure directly influences ventricular afterload and 
reduces the efficiency of cardiac ejection. Indeed, a heart ejecting blood into a 
stiffened arterial system must generate higher end-systolic pressures for a given stroke 
volume, resulting in a greater energy requirement for a given level of blood flow . A 
sustained increase in central systolic blood pressure promotes the development of 
LVH, itself, a major cardiovascular and cerebrovascular risk factor, ultimately leading 
to diastolic dysfunction and heart failure and predisposing to myocardial ischaemia. 
The close relationship between central pulse pressure and LVH is underlined by the 
fact that left ventricular mass is more closely related to pulse pressure in the aorta than 
in the brachial artery .
As discussed previously, the major components of the arterial wall that regulate vessel 
stiffness are elastin, collagen and smooth muscle. With ageing, there is progressive 
disruption and fatigue-ffacture of the elastic load-bearing elements of the arterial wall, 
resulting in a transfer of stress to the more collagenous fibres and an increase in 
arterial stiffness. The resulting rise in central systolic blood pressure aggravates this 
degenerative process, by further increasing the level of cyclical stress and altering the 
absolute and relative amounts of elastin and collagen within the arterial wall , thus 
creating a vicious cycle. Moreover, the widened central pulse pressure is transmitted
18
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to other arteries such as the carotid, which then undergo a process of remodelling to 
reduce wall stress, leading to intima-media thickening .
1.4.2 Isolated Systolic Hypertension
As noted by Bramwell and Hill in 1922, the difference between systolic and diastolic 
blood pressure, the pulse pressure, is directly related to the compliance of the artery 
and the associated change in arterial volume
“Hence the difference between systolic and diastolic pressure, that is the pulse 
pressure, other things being equal will vary directly as the rigidity o f  the arterial
walls. ” 26
Isolated systolic hypertension is defined generically as a wide pulse pressure. The 
BHS definition being: (systolic pressure >160mmHg and a diastolic pressure 
<90mmHg). When arteries are young and elastic, the reflected wave returns during 
diastole. As large arteries stiffen with age and cardiovascular risk factors, PWV 
increases and the reflected wave returns earlier during systole, resulting in increased 
systolic pressure augmentation and increasing central PP. This shift of the reflected 
wave out of diastole results in a simultaneous lowering of diastolic pressure. Changes 
in reflection coefficient (the proportion of forward to backward travelling waves) and 
the major sites of reflection may also contribute to altered magnitude and timing of 
wave reflection and therefore central pressure augmentation. Since there is 
proportionality between cardiac ejection time and the duration of the cardiac cycle, 
the peak of the forward travelling wave will be relatively delayed at slower heart
19
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rates. Therefore, even with a fixed reflection site and speed of wave transmission, 
there will be an altered relationship between forward and backward waves. Central PP 
will therefore be amplified at lower heart rates . Therefore, accounting for heart rate 
differences between groups, when assessing the effects of certain medications (13- 
blockers) on central PP becomes very important.
Interestingly, increased pulse pressure may also be associated with aortic diameter 
change. Traditional views suggest that ISH is associated with increased elastin 
breakdown with secondary collagen deposition and therefore stiffening of the arterial 
wall, leading to a dilated noncompliant vessel. However, a more recent theory 
suggests that ISH may be a result of a reduction in aortic lumen diameter and resultant 
increase in wall tension with normal elasticity 28. Therefore, suggesting a functional 
rather than a structural role of the aorta in the pathophysiology of ISH.
Isolated systolic hypertension can be regarded haemodynamically as a different 
condition to essential hypertension. Essential hypertension is a disease characterised 
by a rise in the static component of blood pressure MAP and DBP and is thus 
influenced by cardiac output and peripheral vascular resistance (PVR). The majority 
of subjects exhibiting increased PVR. Essential hypertension is therefore a disease of 
the smaller resistance vessels. It is more common in younger individuals (<55yrs) and 
is relatively easy to treat as the majority of anti-hypertensive agents are targeted at 
lowering peripheral resistance. In contrast, ISH is a disease of the larger arteries and is 
associated with an increase in the pulsatile component of blood pressure, the pulse 
pressure (PP), which is influenced by stroke volume and large arterial stiffness 
(Figure 1.6). The majority of subjects exhibiting increased large artery stiffness and
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relatively normal peripheral vascular resistance. Again in contrast to essential 
hypertension ISH is more common in older individuals (>55yrs) and is often difficult 
to treat, as available drugs are not specifically targeted at large arterial stiffness. 
Providing a plausible explanation as to why patients with ISH are resistant to a 
number of current therapies . Traditional antihypertensive medication appears to 
reduce arterial stiffness by indirectly reducing mean arterial pressure. The medication 
predominantly acting on PVR to reduce mean arterial pressure. However, medication 
is urgently needed to act on large arteries and reduce large artery stiffness. Nitric 
oxide donors and phosphodiesterase inhibitors have been suggested as possible agents 
for reducing large arterial stiffness. Breakers of advanced end glycation end products 
and collagen cross-links between elastin and collagen proteins have also been 
suggested as potentially beneficial to large artery stiffness29.
Clinically this is important, as increased PP has been demonstrated in the large 
Framingham study, to be a better predictor of cardiovascular events than systolic or 
diastolic pressure alone in people over 50 years 10. This has been confirmed in a 
number of other population-based studies11'13. In the MRC Mild Hypertension Trial, 
PP was shown to be a strong risk factor for coronary events in untreated hypertensive 
male subjects n . In addition, another major population based study in 2,311 subjects, 
the PIUMA study, after a multivariate analysis and adjustment for confounding 
factors, showed that for every lOmmHg increase in PP, there was a 30% increase in 
risk of cardiac events 12. Indeed, a meta-analysis of three large studies, in 7,929 
subjects with ISH, clearly showed PP and not MAP, to be the major determinant of 
cardiovascular risk, in older hypertensive subjects 13.
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Figure 1.6. Cardiovascular determinants associated with ISH and EH. (adapted 
from Physiology; Berne & Levy).
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ISH: Isolated Systolic Hypertension; EH: Essential Hypertension.
1.5 A rte ria l  stiffness and  ca rd iovascu lar  (CV) outcom e
To date, the majority of studies investigating the relationship between arterial stiffness 
and CV outcome have involved measurement of PWV using a variety of different 
methodologies. Furthermore, these studies have been undertaken in defined patient 
populations such as subjects with end stage renal disease (ESRD) 30, hypertension 
31,32and diabetes33.
Blacher et al demonstrated that aortic PWV and age were significantly associated with 
all cause mortality and CV mortality in a group of patients with a mean age of 52yrs 
with ESRD 30. In a cohort of 1,980 hypertensive individuals of 50±13yrs old, a 
significant association between aortic PWV, age, heart rate and history of myocardial
22
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infarction was observed with all-cause mortality and CV mortality, during a 9 year
i
follow up . Furthermore, in a subsequent study by the same group, conducted this 
time in 1,045 hypertensive subjects with no evidence of CHD, aortic PWV was again 
shown to be a significant predictor of primary coronary events and other CV events32. 
Studies have also been performed in subjects with type-2 diabetes. Cruickshank et al 
demonstrated that there was a significant relationship between increased aortic PWV 
and all-cause mortality and CV mortality across a multi-ethnic cohort of 219 diabetic 
subjects33.
Importantly, recent results from three large population based studies involving over 
7,000 subjects, have confirmed the predictive value of aortic PWV in terms of CV 
outcome34-36. The first study to be published was from the Health, Aging and Body 
Composition (Health ABC) study based in Baltimore 34. This study included 2,488 
individuals and after 4.3 yrs of follow up, 616 CV events had been recorded. In 
addition, there were 265 deaths, of which 111 were cardiovascular. The investigators 
divided the cohort into quartiles of aortic PWV and showed that there was a 
significant relationship between aortic PWV and both total and CV mortality. There 
was also a relationship between aortic PWV and stroke. The associations remained 
significant after adjustment for age, race, systolic BP, and known CV disease. The 
following year, results from two further population based studies were reported. The 
Rotterdam study involved 2,835 subjects and followed up for 4.1 yrs. In that time 174 
CV events were detailed. Again, aortic PWV was measured to assess arterial stiffness 
and a significant association was shown between aortic PWV and both coronary heart 
disease (CHD) and stroke. After adjustment for confounding factors aortic PWV 
remained as an independent predictor of heart disease and stroke 35. Finally, results 
from a Danish study involving 1,678 subjects who were followed for 9.4 yrs, during
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which time there were 317 CV events and 171 deaths, of which 62 were 
cardiovascular. They also demonstrated a significant relationship between aortic PWV 
and cardiovascular outcome. Most importantly, in contrast to the other population 
based studies, this study was also able to show that aortic PWV was a better predictor 
of CV outcome than traditional CV risk factors including 24hr MAP 36. Indeed, a 
recent analysis reviewed 97 studies where PWV had been measured in order to assess 
the clinical value of PWV in terms of CV risk prediction. The findings showed that 1 
standard deviation increment in PWV is equivalent to 10 yrs of ageing, or 1.5 to 2 
times the risk of a lOmmHg increase in systolic pressure, suggesting that PWV can be 
used effectively for risk stratification in clinical practice37.
Other Studies investigating the predictive value of arterial stiffness have used AIx as a 
surrogate for arterial stiffness. London et al studied subjects with ESRD and showed 
that carotid AIx was a predictor of both all-cause and C V mortality . More recently, 
Weber et al studied patients undergoing coronary angiography and PCI and
TOdemonstrated that aortic AIx predicted the occurrence of severe CV events
24
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1.6 Arterial stiffness and coronary artery disease (CAD)
A number of studies have been performed relating indices of arterial stiffness to the 
presence of coronary artery disease (CAD). Since the detection of CAD requires 
coronary angiography, the majority of these studies have used invasive methodology. 
A number of small studies have demonstrated a relationship between central PP and 
angiographic CAD 40,4These findings have recently been confirmed in a large multi 
centre study involving 1,337 patients at high risk of CAD from 75 centres 42 which 
demonstrated a significant relationship between invasively determined central aortic 
PP and both the presence and extent of angiographic CAD. The relationship between 
aortic stiffness and angiographic CAD has also been investigated. Both invasive 43 
and non-invasive 44 measurements of aortic stiffness have been shown to correlate 
significantly with CAD. Indeed, Hirai et al demonstrated that aortic stiffness was 
related to the number of atherosclerotic stenoses of the coronary arteries. This data 
has recently been supported by a study demonstrating a significant correlation 
between non-invasive measurement of carotid radial PWV and atherosclerotic plaque 
load as determined by intravascular ultrasound 45. Interestingly, in this study by 
McLeod, AIx measured non-invasively did not correlate with plaque load. Although 
another study has shown a significant association between invasively measured AIx 
and the risk of CHD 46. However, non-invasive measurements are much more 
applicable to the assessment of large patient groups in clinical practice and a recent 
study has shown that non-invasive measurement of AIx does correlate with 
cardiovascular risk 47, although CAD was not assessed in this group of patients. 
Weber et al examined the relationship between aortic AIx and augmentation pressure, 
measured non-invasively with the SphygmoCor system and CAD assessed
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angiographically. 465 consecutive male patients undergoing coronary angiography for 
symptoms of suspected CAD were studied. There was a strong association between 
the presence and severity of CAD and AIx 48. Taken together the results from the 
studies to date are consistent with the hypothesis that central aortic stiffness may 
promote the development of coronary artery disease and that therapeutic intervention 
targeted at reducing arterial stiffness may be of benefit in patients with CAD.
1.7 Factors regulating arterial stiffness
The major factors regulating arterial stiffness can be considered as relating to 
structure, function and mean arterial pressure (MAP) (Figure 1.7).
Until recently, arterial stiffness was thought to be largely dependant upon distending 
pressure and structural components like elastin and collagen. However, it is now 
recognised that smooth muscle tone also regulates arterial stiffness. A number of 
locally produced circulating factors may contribute to the short term and functional 
regulation of smooth muscle tone and hence large artery stiffness. These include 
Nitric oxide (NO), endothelin-1 and natriuretic peptides 49. Of these, NO is probably 
the most important as many conditions exhibiting endothelial dysfunction, 
characterised by decreased bioavailability of NO, are also associated with increased 
arterial stiffness.
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Figure 1.7. Major determinants of arterial stiffness. Structure, Function and
MAP. (Taken from Wilkinson and McEniery 2004)
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Noradrenaline.
1. 7.1 Nitric oxide and arterial stiffness
Endothelial dysfunction, characterised by decreased bioavailability of NO, in 
resistance and conduit arteries is a predictor of cardiovascular risk and outcome 50. 
Conditions associated with endothelial dysfunction such as hypercholesterolaemia 51' 
53 and diabetes 54'56 are also associated with increased arterial stiffness. Furthermore, a
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number of therapeutic interventions that improve endothelial function also reduce 
arterial stiffness 57, suggesting that NO may itself regulate large arterial stiffness. 
Systemic infusions of drugs that promote or inhibit NO release have been used to 
investigate the role of NO in regulating large artery stiffness. Many studies have 
clearly demonstrated that NO donors, such as glyceryl trinitrate (GTN), reduce AIx, a 
composite measure of arterial stiffness and wave reflection, independently of any 
effect on blood pressure in healthy subjects, and in those with a range of 
cardiovascular risk factors including hypertension and hypercholesterolaemia 58. NO 
donors also reduce large artery stiffness in hypertensive individuals 596°, and in 
animals 61, but not always independently of changes in distending pressure. Although 
GTN reduces aortic PWV in animals, again independently from changes in blood 
pressure, such observations have not been repeated in humans.
The contribution of basal NO to resting large artery stiffness has been assessed by 
infusion of various inhibitors of nitric oxide synthase (NOS) including L-N - 
monomethyl-L-arginine (LNMMA) and NG-nitro-L-arginine methyl ester (L-NAME). 
Systemic infusion of LNMMA increases augmentation index in healthy normal 
volunteers , and L-NAME has been shown to decrease small artery compliance 
However, since these studies employed systemic infusions of NOS inhibitors, the 
accompanying rise in MAP made the results difficult to interpret. Stewart et al 
attempted to overcome these limitations by infusing LNMMA, but also noradrenaline 
and dobutamine to control for changes in MAP 64. They showed that systemic 
inhibition of NO had no effect on carotid-femoral PWV over and above that 
attributable to a rise in MAP per se.
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Stewart’s observations demonstrated that the increase in aortic PWV following 
chronic NO inhibition was even greater, which suggests some degree of vascular 
remodelling may have occurred. Therefore, conditions associated with decreased NO 
bioavailability, such as diabetes and hypercholesterolaemia, may affect aortic stiffness 
in the long term by structural modification, thus providing a mechanism linking 
endothelial dysfunction to an increased risk of cardiovascular events.
More definitive evidence for the role of NO in regulating large artery stiffness comes 
from local intra-arterial infusion of LNMMA and GTN. Such techniques overcome 
many of the methodological limitations of systemic infusions because the drug doses 
used are much lower, and if infusion periods are relatively short, MAP and heart rate 
are unusually unaffected. Such an approach can be further enhanced by direct, high 
fidelity, intra-vascular measurement of PWV, using pressure or flow waveforms, or 
distensibility or compliance, using ultrasound. Using such techniques, endothelium- 
derived NO has been shown to regulate large arterial stiffness in the ovine iliac artery 
65. Similar findings have recently been demonstrated in the human iliac arterial bed66.
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1,7.2 Arterial Structure
The constant fracturing and repair of the structural elements of the arterial wall 
ultimately result in stiffening. Therefore age will have a significant effect on arterial 
stiffness as the stress on the arterial wall will be influenced by pulsatile load and heart 
rate. By the time an individual has reached 60yrs, the heart will have beat over two 
billion times. Age is therefore one of the major factors influencing structural changes 
leading to increased arterial stiffness.
Large arteries are made up of a number of different structural proteins. As described 
earlier, it is elastin and collagen that make up the majority of these proteins. Changes 
in the balance between elastin and collagen will therefore influence vascular stiffness. 
Such changes may involve increased synthesis or degradation of elastin or collagen. 
Recent evidence suggests that these proteins are susceptible to chemical attack and 
degradation by a number of proteolytic enzymes, especially serine proteases and 
matrix metalloproteases (MMPs) 67. MMP-9 is particularly involved in the 
degradation of elastin and other basement membrane proteins including fibronectin, 
laminin, and type IV collagen 67. Recently, increased levels of MMP-9 have been 
shown to predict a worse outcome in patients with cardiovascular disease 68. MMP-9 
is also associated with increased arterial stiffness in healthy individuals and risk of 
cardiovascular disease. Support for the involvement of MMP-9 in the regulation of 
arterial stiffness comes from a study which has shown a relationship between MMP-9 
levels and increased arterial stiffness as assessed by carotid femoral PWV in normal 
subjects 67. In addition, a further study by the same group also showed that subjects 
with ISH, a condition characterised by increased arterial stiffness, had increased levels 
of MMP-9 compared to matched controls 67.
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It is now clear that arterial stiffness is, in part, a heritable and dynamic trait 69 
suggesting that genetic make up may influence arterial stiffness. This is supported by 
studies that show a relationship between polymorphisms of a number of genes that are 
involved in the synthesis and breakdown of elastin. A recent study demonstrated that 
polymorphisms of the MMP-9 gene are associated with increased arterial stiffness in
f - t
healthy individuals . Studies have also shown an association between 
polymorphisms in the angiotensin-II gene and increased arterial stiffness 70. Similar 
associations have been reported for polymorphisms within the angiotensin-II receptor
71gene
Finally, hypertension per se has been shown to alter the absolute and percentage of 
elastin to collagen within the arterial wall, leading to further increases in arterial 
stiffness and thus establishing a vicious cycle 49.
1.7.3 MAP
Elasticity of an artery is determined by the mean arterial pressure it is exposed to, and 
its consequent deformation for that applied pressure. The force per unit area that 
produces the deformation is called the stress, the deformation, described as the ratio of 
the deformation to it’s original form, is called the strain . The pressure exerted upon 
the artery has to be considered when assessing arterial stiffness, as the stress strain 
relationship of an artery is not linear. The relationship between stress and strain is 
known as an elastic modulus and defined as, the pressure change required for 
theoretical 100% stretch from resting diameter (AP.D)/AD (mmHg) 72. Where 
P=Pressure, and D=diameter.
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For an ideal elastic body, there is a linear relationship between stress and strain. 
However, arteries are not linear elastic bodies. Figure 1.8, illustrates the elastic 
nonlinearity of an artery, where change in arterial stress (Mean arterial pressure) and 
strain (change in diameter) are expressed in a typical human aorta.
Figure 1.8. The Stress Strain relationship of an artery 29.
Loss o f elasticity 
results in increased
pulse pressure
Stress
(arterial
pressure
Collagen
Elastin
♦  ►
Strain
(relative change in arterial diameter)
Figure 1.8, demonstrates a sequential aspect of the loading of the individual wall 
components that leads to a non-linear response. At lower mean arterial pressures, 
contractile-elastic components are preferentially loaded, whereas as MAP increases 
the load is transferred progressively to collagen. The shift from elastin to collagen 
components of the arterial wall leads to an exponential rise in the stress strain 
relationship due to collagen having little or no buffering capacity on the pressure.
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1.8 Cardiovascular risk factors and arterial stiffness
As we age our arteries get stiffer. However, subjects with cardiovascular risk factors 
exhibit premature vascular ageing. Indeed, vascular age may be a better predictor of 
cardiovascular morbidity and mortality than chronological age as pointed out over 100 
years ago by William Osier.
“Man is as old as his arteries”
73
A number of CV risk factors have since been shown to be associated with premature 
vascular ageing as assessed by increases in arterial stiffness31,33,74. Therefore, for the 
purpose of this thesis, a number of relevant risk factors will be addressed further. 
Smoking as a risk factor for CVD will not be reviewed, as it has recently been 
demonstrated to have no association with arterial stiffness, as illustrated by the ACCT 
study (McEniery et al. In press).
1.8.1 Diabetes mellitus and arterial stiffness
The relationship between diabetes and arterial stiffness has been investigated in a 
number of both large and small studies. Despite the fact that the methodologies for 
assessing arterial stiffness have varied, the findings have been very consistent in 
showing a positive relationship between diabetes and arterial stiffness.
The ARIC study used ultrasound to assess carotid artery stiffness in 4,700 type-2 
diabetics and demonstrated a positive association between diabetes and increased 
arterial stiffness. Furthermore, subjects who were not diabetic, but had impaired 
glucose tolerance also exhibited significant increases in carotid artery stiffness 75. The 
Hoorn study also measured carotid intima media thickness (CIMT) in 1,193
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individuals with either normal glucose levels, impaired glucose regulation or diabetes. 
The study included 301 subjects with type-2 diabetes and in agreement with the ARIC 
study the investigators were able to show a significant relationship between glucose 
tolerance and CIMT. The Hoorn study investigators also measured PP, as a surrogate 
for arterial stiffness in 2,484 subjects of which 208 were type-2 diabetics 76. They 
demonstrated a positive association between PP and CV mortality. This has been 
confirmed in another study in 2,911 subjects with diabetes in which PP was shown to 
be a better predictor of CV outcome than either SBP or DBP 11. Subsequently a larger 
study, the FinnDianne study 78, also examined the relationship between type-1 
diabetes and PP. This study compared 2,988 type-1 diabetics and 5,486 non-diabetic 
controls across a wide age range. Again, there was a significantly higher PP in the 
diabetic group. Also, the age related increase in pulse pressure was greater in the 
diabetic group and consequently there was a greater prevalence of ISH in the diabetic 
group. Furthermore, the age related rise in PP was more pronounced in diabetic 
individuals with nephropathy. However, although these studies included large 
numbers of patients and were consistent in their findings, they were non the less cross 
sectional and do not provide adequate insight into cause and effect. However, a study 
by Hopkins et al in 1996, using doppler ultrasound as a measurement of arterial 
stiffness demonstrated that family history of type-2 diabetes is associated with 
decreased aortic distensibility in normal healthy young adults 79.
A number of smaller studies have also measured arterial stiffness in subjects with 
diabetes. Early studies performed by Wahlqvist et al in 1988 used ultrasound to 
measure aorto-iliac PWV and showed it to be significantly higher in the diabetics 
relative to controls. These findings were confirmed in a later study employing similar
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fin fi imethodology ’ . A more recent study measured aortic PWV in Japanese men and 
showed that aortic PWV was significantly higher in diabetics compared to healthy 
controls 82.
Differential effects of diabetes on central elastic, and peripheral, more muscular 
arteries has also been the focus of investigation. Kimoto et al 2003, measured PWV in 
the aortic, carotid, brachial, and femoral artery beds in diabetic subjects and controls 
and demonstrated that the central arteries of diabetics stiffen at an accelerated rate 
compared to peripheral arteries. Furthermore, they showed that diabetes was only 
significantly associated with PWV in the central arteries 83. A similar study by 
Cameron et al 2002, has investigated the differential stiffening of central and 
peripheral arteries in diabetics and controls and also shows a significant difference in 
the rate of age-related increase in vascular stiffness in the elastic arteries of diabetics 
compared to non-diabetic controls. The diabetic arteries appearing to age at an 
accelerated rate from an earlier age and then reach a functional plateau 84.
However, not all studies have shown a positive relationship between diabetes and 
arterial stiffness. Initially, Scarpello et al 1980, demonstrated that carotid artery, 
brachial artery and femoral artery distensibility were not significantly different 
between diabetics and non-diabetics, as assessed by doppler ultrasound. More 
recently, investigators have demonstrated no difference in large artery stiffness 
(carotid, brachial or femoral) using ultrasound and stiffness index (SI) 85,86 and also no 
significant difference in CF PWV between diabetics and controls86.
The introduction of the sphymoCor system has made it possible to use PWA to study 
arterial stiffness in a variety of patient populations and a number of investigators have 
employed this technique to compare diabetics and controls. One of the first studies
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assessed AIx and central pressure as a measure of arterial stiffness in a group of type- 
1 diabetics and controls, and demonstrated a significant increase in both AIx and 
central pressure in the diabetic group 87. This was subsequently confirmed in another 
study using similar methodology 55. In this study, AIx was also significantly higher in 
the type-1 diabetic individuals. In addition the investigators measured the time to 
return of the reflected wave (Tr), as a surrogate for aortic PWV and showed that this 
too was increased in the diabetic group. PWA has also been used to investigate 
arterial stiffness in subjects with type-2 diabetes. A study by Brooks et al compared 
88 subjects with type-2 diabetes and 85 controls. As with type-I diabetes, the subjects 
with type-2 diabetes also exhibited a significantly higher AIx when compared to 
controls 88
Recently Lacy et al, in 2004, also used PWA to study differences between a mixed
fiOcohort of type-1 and type-2 diabetics . CF PWV was increased in the diabetics 
relative to controls, in agreement with previous studies. However, AIx was not 
significantly different between diabetics and non-diabetics. A potential explanation 
for this, is, the age of the subjects studied. Subjects of Lacy et al’s were 55yrs or 
older, whereas the subjects in both the previous studies 87,88 were younger. 
Unpublished data from our own study group and others have recently demonstrated 
that in normal individuals, AIx tends to plateau at around age 55yrs (Figure 1.9). 
Indeed one study has shown a decrease in AIx after age 55 yrs 90, making it more 
difficult to demonstrate changes in AIx in younger age groups. However, CF PWV 
increases relatively little to age 55yrs and then rises steeply making it more likely that 
changes in CF PWV due to diabetes will be more easily distinguishable. Diabetes 
induces little shift in the age AIx relationship over 55yrs but produces large shifts in
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the CF PWV age relationship in subjects over 55yrs (Figure 1.9). This is important as 
it suggests that AIx will be more predictive of risk in younger subjects with diabetes 
whereas CF PWV should be more predictive in older subjects.
Although a considerable number of intervention studies have demonstrated decreased 
arterial stiffness in different patient populations, there is less published data in 
subjects with diabetes. In general therapeutic interventions that have been shown to 
improve endothelial function have been successful in reducing arterial stiffness. One 
early study showed that 6-weeks treatment with fish oil decreased arterial stiffness as 
assessed by an improvement in oscillatory compliance in 20 patients with type-2 
diabetes91. Vitamin C therapy also decreases arterial stiffness, assessed by PWA, in 
type-2 diabetics treated for 1 month . Furthermore, type-2 diabetics treated with 
atorvastatin also exhibited a decrease in femoral PWV 93. Esposito et al in 2004 have 
also illustrated that control of postprandial hyperglycaemia but not fasting 
hyperglycaemia was associated with a reduction of CIMT using repaglinide and 
glyburide over a 12 month period, in type-2 diabetics94. Finally, Laurent et al were 
able to demonstrate that ACE inhibition with perindopril was able to decrease carotid 
distensibility independently of changes in blood pressure in a group of hypertensive 
type -2 diabetic subjects 95.
Overall the majority of data are consistent in showing that diabetes is associated with 
increased arterial stiffness. However, there are as yet no large longitudinal studies so 
that cause and effect remain unclear. Furthermore, the increasing incidence of obesity 
and the pre-diabetic metabolic syndrome make it important to study the relationship 
between states of abnormal glucose metabolism and arterial stiffness.
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Figure 1.9. The general trend of AIx and CF PWV with age, in diabetics and 
non-diabetics. Taken from the ACCT study group database, 2007.
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1.8.2 Impaired glucose metabolism and arterial stiffness
In contrast to overt diabetes, far less studies have investigated the relationship 
between abnormal glucose metabolism and arterial stiffness. The large Rotterdam 
study, involving 2,987 elderly normal subjects has shown a positive relationship 
between impaired fasting glucose (IFG) and arterial stiffness, as assessed by carotid 
arterial distensibility. However, this observation was only apparent after the age of 
75yrs 96. The Hoorn study has also examined the association between impaired 
glucose metabolism, defined as a combination of IFG and impaired glucose tolerance 
(IGT) and arterial stiffness, assessed by PP and CIMT, in 1,193 individuals with 
either normal glucose levels, impaired glucose regulation or diabetes. However, this 
study only demonstrated an association between brachial and femoral IMT and 
impaired glucose metabolism and did not observe any association between these 
groups in the carotid vascular bed. Unfortunately, the study did not report findings in 
the IFG as separate group in their analysis. 97
Subsequently, the same group employed PWA to assess arterial stiffness within the 
same cohorts as their previous study. Again, subjects with IFG were considered 
together with subjects with IGT. There was no difference in AIx between the impaired 
glucose metabolism group (IFG and IGT) and controls 98. Again the mean age was 
68yrs so that as suggested previously differences in AIx would be difficult to 
demonstrate. The investigators did not measure CF PWV or CV outcome. A study by 
Cruickshank et al in 2002, examined the relationship between arterial stiffness and 
CV outcome in subjects with normoglycaemia, abnormal glucose metabolism and 
type-2 diabetes. Again no distinction was made between IFG and IGT. Arterial 
stiffness was assessed by measuring aortic PWV. Aortic PWV was raised in both the
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diabetic and impaired glucose metabolism groups and was shown to correlate 
positively with mortality 33.
To date, few studies have examined the relationship between arterial stiffness and IFG
with conflicting results. In one study 2,080 Japanese men were investigated and
exhibited a positive relationship between brachial-ankle PWV and IFG However,
the results of this study are difficult to interpret, as subjects were hypertensive and
PWV was assessed using brachial-ankle PWV, which unlike CF PWV has not been 
• 100shown to predict outcome . A similar smaller study in 282 Japanese, also measured 
brachial- ankle PWV and showed a positive correlation with IFG 101.
Further studies failed to show any association between IFG and arterial stiffness, as 
assessed by CIMT 102 and PWA 103. Furthermore, a reduction in post prandial 
hyperglycaemia but not fasting hyperglycaemia in diabetics was associated with 
CIMT reduction94 and in a study which assessed the second derivative of 
plethysmogram as a measure of arterial stiffness, 2hr post challenge hyperglycaemia 
and not fasting glucose was associated with increased arterial stiffness104. Impaired 
glucose metabolism is an important component of the metabolic syndrome which has 
been shown to correlate significantly with increased arterial stiffness 105 106. However, 
no studies apart from the ones just cited and discussed in chapter 5 have separated 
IFG from impaired glucose metabolism or attempted to analyse the components of the 
metabolic syndrome separately in terms of the individual effects on arterial stiffness. 
Since obesity is strongly associated with abnormal glucose metabolism and the 
metabolic syndrome, it has been difficult to tease out the relationship between various 
components of the metabolic syndrome and arterial stiffness. This is especially true 
for insulin resistance and obesity.
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1.8.3 Obesity, insulin resistance and arterial stiffness.
Studies examining the relationship between obesity and arterial stiffness are difficult
to fully interpret as they are confounded by a number of factors. Including whether
obesity is defined by BMI or waist circumference. In addition, some studies have 
»
made distinctions between visceral and abdominal fat. Clustering of other risk factors 
such as hypertension, insulin resistance and inflammation also make accurate 
interpretation problematic. Finally, the degree of insulin resistance will vary within 
obese populations.
CF PWV was measured in 1,014 middle-aged subjects, with no clinical evidence of
CV disease, enrolled in the SU.VI. MAX study 107. CF PWV was significantly
correlated with obesity assessed by increased waist circumference. A further large
study involving 2,488 older adults showed in a multivariate regression analysis that
obesity defined by abdominal visceral fat was positively associated with aortic PWV
108. Van Popele et al measured carotid distensibility in 180 non-diabetic women.
There was a significant correlation between BMI, waist hip ratio and carotid
100distensibility. This relationship remained significant after adjusting for MAP 
Smaller studies examining the relationship between obesity and arterial stiffness have 
been conflicting. This may be due in part to the different subject characteristics. In 
subjects with hypertension, brachial PWV was significantly increased in obese 
subjects with increased BMI’s relative to lean controls. Furthermore, there was a 
positive relationship between obesity and PWV, which remained significant after 
adjustment for glucose, lipids and triglycerides (TG’s) uo. A study in severely obese 
children has demonstrated increased arterial stiffness, assessed by ultrasound. This 
was also associated with endothelial dysfunction m . However, in a study that
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measured BMI and aortic PWV in 524 healthy young adults, multiple linear 
regression analysis failed to show an association between BMI and aortic PWV 112.
A number of intervention studies have also reported the effect of weight loss on 
arterial stiffness. A study involving 152 individuals followed for 2 years, showed that 
a weight gain of > 4.5 Kgs was associated with a significant increase in aortic PWV. 
In contrast subjects who lost > 4.5 Kgs in weight exhibited a significant decrease in 
aortic PWV 1I3. A study in 38 obese patients with type-2 diabetes showed that weight 
loss after a period of 1 year was associated with a significant decrease in aortic PWV 
114. Weight loss in a small study of overweight adults was associated with a significant 
improvement in brachial artery compliance. This was associated with an 
accompanying improvement in lipid profile and insulin sensitivity 115. An association 
between obesity and insulin resistance has been reported in adults and children. 
Studies in children by Caprio et al in 1996 employing a hyperinsulinaemic 
eucglycaemic clamp technique, demonstrated that insulin resistance and 
hyperinsulinaemia co-exist with various extremes of obesity 116.
The ARIC study measured serum insulin levels and demonstrated a graded 
relationship between fasting insulin and arterial stiffness 75. Similar findings were 
reported from the Health ABC study in which insulin levels were correlated with
1 Afiincreased aortic PWV in 2,488 subjects . A large Danish population study measured 
fasting insulin levels in 2,420 men and women subjects. Hyperinsulinaemia was 
associated with increased aortic PWV which remained significant in a multiple 
regression analysis controlling for conventional risk factors 117. A number of studies 
have used the hyperinsulinaemic euglycaemic clamp to investigate the effects of 
insulin on arterial stiffness in normal subjects, insulin resistant subjects and type-2 
diabetics. In normal subjects, insulin at physiological levels decreases wave reflection
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1 152and AIx . Furthermore, the same investigators demonstrated that this effect of 
insulin was blunted in obese insulin resistant subjects 119 and in subjects with type-1 
(Westerbacka et al Hypertension 2000) and type-2 diabetes 12°.
1.8,4 Physical Activity and arterial stiffness
Lack of physical activity is an independent risk factor for CVD 121,122. Although it has 
been demonstrated that increased physical activity decreases blood pressure, it’s effect 
on arterial stiffness remains unclear 123.
Major large-scale studies have focused on the beneficial effects increased physical 
activity has on arterial stiffness. One such study, performed by the Northern Ireland 
Young Hearts Project involving 405 young subjects (12-15yrs) showed an inverse 
relationship between estimated cardio respiratory (CR) fitness and self reported 
physical activity (PA) levels with arterial stiffness, assessed by 
photoplethysmography which measured aorto-iliac and aorto-dorsalis pedis PWV 124. 
These findings have been confirmed in a recent similar sized population based study 
of 432 healthy young to middle age subjects. This study measured CIMT and carotid 
stiffness and showed a significant inverse correlation between habitual physical 
activity and both CIMT and carotid stiffness 125. However, not all large studies are in 
agreement with this data. The ARIC study involving 10,644 older individuals who 
performed habitual exercise demonstrated no association with decreased arterial 
stiffness, as assessed using CIMT and habitual physical activity. However, vigorous 
PA was shown to have a weekly positive association with decreased arterial stiffness, 
again measured by CIMT 126. A much smaller study has confirmed these findings, 
showing that a habitual recreationally active group of men did not exhibit any
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significant differences in arterial stiffiiess, measured at the carotid artery using B 
mode ultrasound and applanation tonometry, compared to a sedentary control group. 
However, a significant difference in arterial stiffness was observed between an 
endurance trained group and both recreationally active and sedentary groups, assessed 
again using B mode ultrasound and applanation tonometry 127.
Interestingly, earlier smaller studies have shown that leisure time physical activity 
(LTPA) was associated with decreased arterial stiffness, assessed by doppler 
ultrasound and Young’s elastic modulus. However, it was also established that higher 
LTPA had significantly lower arterial stiffness compared to the lower LTPA 128. 
Suggesting that CR fitness may, in part, have a role to play in decreasing arterial 
stiffness. Indeed, it has been demonstrated that increased CR fitness (measured by 
VC^max), is associated with decreased arterial stiffness as measured by AIx and
19Qaortic PWV, in 146 men aged 54-75 yrs . Cardiorespiratory fitness was also shown 
to be inversely associated with AIx in a group of 201 men, aged approximately 50yrs 
without CHD. However, the subjects used in this study were a mixture of 
hypertensives, diabetics and smokers, making interpretation of the results very
1 “70difficult . Similar findings have been demonstrated in females. Both moderate and 
vigorous PA levels in postmenopausal women were associated with decreased arterial
11ffstiffness, assessed by carotid (3 stiffness index . These studies were however, cross 
sectional and thus provide no data on cause and effect relationships.
Longitudinal studies, like the DANSCO study have shown that regular low to 
moderate intensity aerobic exercise is associated with a 40% lower 6-year progression 
of CIMT compared to a group taking little or no exercise 131. The ACT study 
demonstrated that increased PA was associated with a significant decrease in aortic 
PWV in 555 men and women, aged 35-75yrs after 24 months of walking intervention
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132. A much smaller interventional study, of 16-weeks low to moderate exercise was 
performed on 17 sedentary men, and showed a significant decrease in arterial stiffness 
of the central elastic arteries and no difference in the peripheral muscular arteries, 
assessed using PWV. Suggesting that like age, physical activity may have a 
differential effect on the central arteries compared to the peripheral arteries. 
Interestingly, findings by Tanaka et al 1998, had already observed that age related 
increases in arterial stiffness, as measured by aortic PWV, were not apparent in 53 
highly PA women 133. Interestingly, although ISH is associated with increased large 
arterial stiffness, a small study failed to show benefit of aerobic exercise on large 
arterial compliance 134. However, the same group was able to show that cholesterol 
reduction did decrease arterial stiffness in a similar group of subjects with ISH, so this 
result is perhaps surprising as exercise has been shown to decrease cholesterol levels
134
Indeed, a major potential limitation of these interventional studies is that they may be 
confounded by the effect of exercise on other CV risk factors, including blood glucose 
. Especially since exercise has been shown to increase insulin sensitivity and therefore 
improve glucose levels 136. Indeed, the effect of short-term aerobic exercise was 
shown to decrease arterial stiffness, assessed by p stiffness index at the carotid and 
femoral site, in type-2 diabetics. Furthermore a number of other studies have 
demonstrated that physical inactivity is associated with adverse metabolic effects such
1 T7 1 TOas increased fasting glucose and raised triglycerides (TG’s) ‘ . Increased PA,
especially via aerobic exercise has also been shown to alter gene expression e.g. 
Prostaglandin, C-type Natriuretic Peptide (CNP) and endothelial Nitric Oxide 
Synthase (eNOS). Expression of these genes, especially nitric oxide in the aorta, may
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be in part an explanation for the beneficial effect seen by aerobic exercise on aortic 
stiffness 140.
Finally, the majority of data suggests the beneficial impact that increased physical 
activity has on arterial stiffness and overall CV risk. However, further longitudinal 
and interventional studies are needed to demonstrate cause and effect. Various ranges 
of intensity levels and forms of PA need to be considered, along with biochemical 
measures relating to endothelial function need attention in these proposed longitudinal 
studies to demonstrate the causal determinants of decreased arterial stiffness and CV 
risk.
1.8.5 Ethnicity and arterial stiffness
To date, although there is some published data on differences in ethnic background 
and arterial stiffness, data is mostly confined to studies comparing Black Afro- 
carribeans and Caucasians. African Americans have been demonstrated to exhibit 
accelerated large arterial stiffening when compared to Caucasians 141. Furthermore, in 
a separate study they show a greater pressure-dependant increase in aortic stiffness 142. 
These results suggest that there are major differences in the mechanical properties of 
the large arteries between the two ethnic groups.
In contrast, very little data has been published comparing South Asians and 
Caucasians when assessing arterial stiffness and vascular haemodynamics. Although a 
recent multiethnic study measuring aortic PWV in subjects with diabetes and impaired 
glucose metabolism included a group of South Asians, but no data for the South 
Asians were presented separately33.
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Studies have however, examined differences in CV disease between South Asians and 
Caucasians. Following an 11 year follow up study by Mather et al, 1998, investigators 
demonstrated that 77% of all South Asian deaths are caused by circulatory disease 
compared to 46% in Europeans 143. Furthermore, it has also been shown that South 
Asian men have a 60% greater rate of CHD related death compared to white European 
men. However, 50% of all deaths in South Asians are associated with diabetes 
mellitus compared to only 13% of deaths associated with diabetes in white Europeans
144
Interestingly, although South Asians have similar prevalence of ischaemic heart 
disease (IHD) to Caucasians, the prevalence of PVD is considerably lower. A study of 
clinical features and vascular complications of diabetes between migrant Asians and 
Caucasians in Leicester illustrated the prevalence of PVD as 3% in the South Asians 
versus 9.3% in the Caucasian, P<0.05 145. This remains a consistent finding even in 
the presence of classical risk factors such as diabetes 146. Furthermore, a recent study 
has demonstrated that South Asians have a lower risk of amputation compared to 
Europeans and that this was related to lower prevalence of neuropathy and PVD 147. In 
this study by Chaturvedi et al, investigators demonstrated that South Asian diabetics 
have about a quarter of the risk of amputation of Europeans.
The mechanisms associated with these findings are unclear. However, if arterial 
stiffness precedes atherogenesis, then a plausible explanation would be that the 
femoral vascular bed of South Asians exhibits a lower rate of age related stiffening 
than that of Cauacasians. This hypothesis will be investigated in this thesis.
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1.8.6 Cholesterol and arterial stiffness
Unlike diabetes, the relationship between cholesterol and arterial stiffness is less 
consistent. This may be due to a number of factors including differences in the 
methodologies used to assess arterial stiffness and the vascular bed that the 
measurements were made in. Studies have also reported results for different lipid 
components ranging between LDL, total and HDL cholesterol. In addition, some of 
the patient populations studied had additional risk factors such as hypertension. 
Finally, there is also considerable age variation between the studies reported. Indeed, 
one of the earliest studies performed in children with familial hypercholesterolaemia 
(FH), Lehamnn et al, 1992, demonstrated a positive relationship between low density 
lipoprotein (LDL) and decreased arterial stiffness, assessed by measuring aortic 
distensibility using ultrasound. The study also demonstrated an inverse relationship 
between arterial stiffness and HDL,148. Interestingly, when the investigators measured 
the same parameters in an adult cohort, the reverse was found with there now being a 
positive relationship between LDL and total cholesterol (TChol) and increased arterial
fi 1stiffness . These studies were small and a number of larger more recent studies have 
examined the relationship between cholesterol and arterial stiffness. Pitasavos et al, 
1998, demonstrated a positive correlation between LDL cholesterol and increased 
arterial stiffness in 60 subjects with FH, compared to 20 normochoesterolaemic 
controls 149. However, these findings were not confirmed by a smaller study using 
similar methodology in 25 patients with FH and 10 controls, which demonstrated no 
significant difference in aortic or carotid stiffness between groups 51. These studies 
assessed aortic stiffness using ultrasound. A further study by Giannattasio et al, 1996, 
assessed arterial stiffness in the radial artery and demonstrated that radial artery 
stiffness, assessed by ultrasound derived radial compliance, was significantly greater
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in a group of subjects with FH compared to controls 150. Studies involving subjects 
with FH have reported on extremes of cholesterol. Other studies have been undertaken 
in subjects with cholesterol more representative of those found within the general 
population.
Recent studies have used PWA to study arterial haemodynamics in 
hypercholesterolaemic subjects and controls. Interestingly, investigations carried out 
by Dart et al, 2004, in a cohort of 868 hypertensives demonstrated no relationship 
between TChol and arterial stiffness, when measured by AIx 151. Interestingly, this 
study was conducted in a population over 65yrs. The group was also hypertensive, 
making interpretation of the results difficult. In contrast to this study, a further study 
performed by Wilkinson et al, in 2002, demonstrated that arterial stiffness assessed by 
AIx, and central blood pressure were significantly higher in a hypercholesterolaemic 
group compared to matched healthy controls, despite no differences in peripheral 
blood pressure. In addition, there was also a positive relationship between AIx and 
LDL cholesterol . Overall, the majority of studies demonstrate a positive 
relationship between raised cholesterol levels and increased arterial stiffness, 
suggesting that cholesterol reduction may decrease arterial stiffness.
Indeed, a study by Ferrier et al was able to show that cholesterol reduction in subjects 
with ISH, a condition characterised by increased arterial stiffness, not only improved 
systemic arterial compliance but also resulted in small but significant reductions in
1 ^ 7peripheral systolic pressure . Interestingly these patients were not 
hypercholesterolaemic. A number of further studies have addressed the effects of 
cholesterol lowering therapy, mostly with statins, and arterial stiffness, in cohorts with 
hypercholesterolaemia. The results having been conflicting. Whilst Kool et al were 
unable to demonstrate any effect of statin therapy on either carotid, brachial or
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femoral arterial distensibility , Muramatsu et al were able to show decreased aortic 
PWV in hypercholesterolaemic subjects after 6 months statin therapy. Possible 
mechanisms for the reduction in aortic PWV were suggested as the decrease in 
cholesterol levels, which resulted in an improvement in peripheral endothelium- 
dependant vasodilation disorder associated with hypercholesterolaemia. Moreover, 
this effect was still present at 5 years 154.
To date the majority of studies would tend to support the benefits of cholesterol 
reduction on arterial stiffness. A number of questions however remain unanswered. 
There is a clear association between stiffening of the arterial wall (arteriosclerosis) 
and atheromatous deposition (atherosclerosis). Therefore stiffening may reflect 
atherosclerosis rather than a direct effect of cholesterol on the arterial wall. Future 
studies designed to better understand causality will need to include much larger 
cohorts than those studied to date and particularly include younger individuals free 
from clinical evidence of CV disease in order to minimise the confounding effects of 
pre-existing atheromatous disease and CV risk factors. As with diabetes and IFG, 
there is a major need for large longitudinal studies.
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METHODOLOGY 
2.1 Introduction
This chapter briefly describes the methods used for recruiting study volunteers and 
their selection, but more details are provided in the relevant chapters. However, the 
various techniques used to assess arterial stiffness are addressed in more detail in this 
chapter.
2.2 General recruitment process
Recruitment of volunteers was performed through a self-referral risk factor clinic. A 
constant throughput of volunteers enabled recruitment of an appropriate number of 
subjects needed for each study. Specific recruitment procedures and ethical issues are 
addressed in the methodology section of each chapter accordingly.
2.3 Measurements
2.3.1 Blood Pressure (supine and seated measurements)
Blood pressure and other haemodynamic measurements were performed after ten 
minutes rest in a temperature controlled room. Blood pressure was measured at the 
brachial artery using a validated semi-automated oscillometric device155. All 
measurements were taken on the dominant arm and in duplicate to rule out any 
discrepancies and mean values were used in the subsequent analysis. All 
measurements were obtained according to BHS guidelines156.
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2.3,2 Measurement o f vascular haemodynamics, using three non-invasive 
systems.
The SphygmoCor, Gaon21A and PP-1000 were used to measure various indices of 
arterial stiffness. The SphygmoCor and Gaon21A systems individually use 
applanation tonometry and PWA to derive the augmentation index (AIx). The 
SphygmoCor and PP-1000 systems were used to measure regional artery PWV.
2.3.2.1 SphygmoCor system
2.3.2.1.1 Applanation tonometry.
Arterial stiffness was measured using the method of applanation tonometry. 
Applanation tonometry was initially used by Mac Kay and Marg in 1960, for the 
investigation of intraocular pressures157. This theory relied on the elimination of 
circumferential wall stresses by flattening a portion of the chamber and allowing a 
central cantilever beam to respond directly to intraocular pressure. The principles of 
this were used by O’Rourke and Gallagher in 1996, to record high fidelity waveforms 
from peripheral arteries and termed pulse wave analysis (PWA) 16. The investigators 
showed that once the artery is flattened, circumferential pressures are equalised and 
transluminal pressures can be recorded accurately. In fact, Kelly 17 demonstrated 
intra-arterial pressures can be recorded with a high degree of accuracy. Radial artery 
waveforms are recorded with a high-fidelity micromanometer (SPC-301; Millar 
Instruments, Texas, Houston) from the radial pulse at the wrist of the dominant arm. 
The hand held Millar tonometer consists of a pencil shaped probe with a high fidelity 
micromanometer at its tip. The tip consists of a 0.5 x 1mm piezoelectric crystal with a 
frequency response rate greater than 2kHz, which is co-planar with a 7mm face 
allowing direct applanation of the artery under study. (See Figure 2.1).
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2.3.2.1.2 Pulse wave analysis (PWA)
Peripheral artery waveforms are recorded using the Millar hand-held tonometer at the 
radial artery and analysed using the SphygmoCor software (Figure 2.1).
Figure 2.1. The Millar hand-held tonometer, applanating the left radial artery 
with the obtained waveform being demonstrated in the background
Calibration of the device is performed using the brachial blood pressure taken from 
the dominant arm, using a validated automated oscillometric sphygmomanometer
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(HEM-705CP, Omron Corporation, Japan). Two measurements are made and an 
average used for later analysis. The pulse trace is recorded for ten consecutive beats, 
with a subsequent pulse train being averaged and processed by the inbuilt software 
package.
The system uses a method known as Fourier analysis to break down the averaged 
radial pulse wave recorded, split it into its component harmonics and uses a transfer 
function to recreate a central aortic waveform. (Figure 2.2). Although the use of a 
generalised transfer function has been the subject of some criticism, a number of 
studies have proven its validity 18>19>158. Pauca et al, demonstrated in an invasive 
comparison, that the absolute difference between estimated (via transfer function) and
1 ftactual central pressures was less than ImmHg
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Figure 2.2 Data recorded by the SphygmoCor system (version 8.1), displaying 
results of PWA.
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For the purpose of this thesis, the most relevant parameters recorded from the 
waveform include central blood pressure, heart rate (HR), ejection duration (ED), 
augmentation index (AIx), HR adjusted AIx, augmentation pressure (AP) and time for 
the reflected wave to return (Tr). Figure 2.3 describes the morphology and sites of 
relevant information of a typical aortic waveform constructed by the SphygmoCor 
system.
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Figure 2.3 A typical aortic pressure waveform constructed by the SphygmoCor 
software.
Tf: Foot of the forward travelling wave, Tr: time difference between the foot of the 
wave and the point at which the reflected wave has an effect (the inflection point), PI 
& P2: first and second systolic peaks, PP: pulse pressure.
AIx is measured as the difference between the first (PI) and the second (P2) of the 
systolic peaks and recorded as a percentage of the pulse pressure (PP). The first 
systolic peak is the maximum pressure the forward travelling wave expresses and the 
second systolic peak, is the peak generated after the influence of the forward and 
backward travelling waves are combined. AIx is also a measure of wave reflection. 
One of the main sites of wave reflection is the aortic bifurcation. Since AIx is 
influenced by aortic PWV and the site and magnitude of wave reflection from the 
periphery it can be considered as an indirect measure of arterial stiffness. Further 
analysis of the recorded wave forms can be made to obtain values of central blood 
pressure, HR and Tr, which is the time taken for the reflected wave to return and is
Incisura
PP
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therefore a reasonable surrogate for aortic PWV 159. Guidelines for the use of PWA in 
research and clinical practice have recently been published 16°. The guidelines 
addressed in this paper refer to the importance of a standardised procedure for 
measuring PWA. The investigators also discuss the importance that confounding 
factors like blood pressure, age, gender, BMI, heart rate and medication have on 
PWA.
2.3,2,1,3 Pulse wave velocity (PWV)
Although PWA and indices such as AIx have been measured in a large number of 
studies, as yet, AIx has not been shown to be a major predictor of CV outcome. PWV 
has been established as the “gold standard” for assessing arterial stiffness in a variety 
of arterial beds. However, it is aortic PWV (usually assessed as carotid-femoral PWV) 
that has been shown to be predictive of outcome (See Chapter 1, Section 1.5) and not 
PWV in other vascular beds such as the brachial and femoral 10°.
Using the SphymoCor system aortic, brachial, and femoral PWV can be measured as 
the time taken for the pulse to travel from the R-wave of a three lead ECG-gated 
signal, to the first upstroke of the pulse wave at the carotid, radial, femoral and 
dorsalis pedis arterial site. To calculate PWV it is necessary to determine the path 
length. This is achieved by surface measurement of the distance between the carotid 
brachial or carotid femoral measurement sites. (In practice this is done by measuring 
the distance from the supra-stemal notch to the site of measurement, over and across 
the surface of the body). A three lead ECG is attached to the subject in this instance to 
obtain an ECG signal for software analysis.
Waveforms are measured sequentially at each location, whilst the signal is 
simultaneously being gated from the R-wave of the ECG. The measurement is
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therefore recorded from the R-wave of the ECG to the foot of the forward travelling 
pulse wave. The foot of the pulse is used as the identification point of the wave 
because the foot is the only area of the wave that is not influenced by wave reflection. 
The intersecting tangent algorithm is used in the determination of where the upstroke 
or point of recording ends.
23,2,2 Gaon21A system (Hanbyul Meditech Co,, Korea)
23.2.2.1 Applanation tonometry
Like the SphymoCor system this system also uses applanation tonometry to measure 
peripheral pulse waveforms and generate the AIx. However, unlike the SphymoCor 
system this method of applanation tonometry uses a larger pressure sensor mounted 
onto a radial wrist clamp (Figure 2.4). To date, this system has yet to be validated 
against the SphymoCor system in terms of AIx.
23.2.2.2 Pulse wave analysis (PWA)
This simple to use method of measuring AIx has only recently been developed. 
Applanation of the radial artery is performed and the pressure sensor located directly 
over the artery (Figure 2.4). Various degrees of pressure can then be applied to obtain 
clear waveforms. The pulse trace is the recorded for ten consecutive beats, with a 
subsequent pulse train being averaged and processed by the inbuilt software package. 
The Gaon21 A uses the method of Fourier transformation analysis to break down the 
averaged radial pulse wave recorded, similar to that performed by the SphygmoCor. 
This system can only be used to measure AIx as there is no data on the validity of the 
integral transfer function to measure central arterial pressure.
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Figure 2.4 Measurement of AIx, using the Gaon21A system.
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2.3.2.3 PP-1000 system (Hanbyul Meditech Co., Korea)
Methodology
2.3.2.3.1 Applanation tonometry
Again, this system utilises applanation tonometry to accurately record peripheral 
arterial waveforms. However, unlike the SphygmoCor system which uses the Millar 
hand-held tonometer, the PP-1000 uses gel-filled semiconductor pressure sensors, 
designed to measure the applied pulse pressure from the artery. Sensors are attached 
to elastic, Velcro attaching bands, which were easily strapped around the approximate 
artery area, with the sensor directly over the artery bed. Unlike the SphygmoCor and 
Goan21A systems, the PP-1000 does not incorporate an integral transfer function and 
so cannot be used for measuring AIx from a generalised central aortic waveform.
2.3.2.3.2 Pulse wave velocity (PWV)
Using the PP-1000 (Hanbyul Meditech Co., Korea), regional PWV values based on 
measurements of electrocardiography (ECG), phonocardiography (PCG), and pulse 
waves from four different artery sites (carotid, femoral, radial, and dorsalis pedis) can 
be obtained simultaneously. ECG signals are acquired from both right and left 
forearms, and PCG sensor, which incorporates a piezopolymer film contact 
microphone, is placed on the chest. Sensors are attached to elastic, Velcro attaching 
bands, which are easily strapped around the approximate artery area, with the sensor 
directly over the artery bed. The sensor applied over the carotid artery is applied using 
a spring-mounted clamp. Similar to the Velcro straps on the peripheral arteries, 
increased pressures can be applied to the clamp in order to obtain a clear waveform. 
Figure 2.5 shows the sensors and the Velcro strapping used by this apparatus.
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Cut-off frequency of analogue filters for pulse waves is set at 0.05~20Hz. ECG and 
four pulse waves from carotid, radial, femoral, and dorsalis pedis arteries are 
measured on the left side of the body and recorded simultaneously for the duration of 
10 seconds. Like the SphygmoCor system, the PP-1000 uses foot to foot 
methodology. PWV is recorded as the velocity of the pulse wave from the R wave of 
the ECG gated signal to the upstroke of the simultaneously recorded pulse waves at 
each artery site. However, unlike the SphygmoCor system, the PP-1000 records pulse 
waves at all four arterial sites simultaneously (Figure 2.6).
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Figure 2.5 Sensor and Velcro strap used by the PP-1000 system.
Figure 2.6 PWV measurements recorded simultaneously by the PP-1000.
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For an automatic determination of PWV values, surface distances between the two 
recording pulse waves are measured and inputted to the system to allow the 
calculation of PWV values. PWV= Distance / ATime (m/s).
Once data collection is finished, the system extracts characteristic points from each 
signal. R-peaks of ECGs are detected using a time division adaptive threshold 
algorithm. Based on the time-domain scales obtained from the above values, upstroke 
points of pulse waves at the carotid, radial, femoral, and dorsalis pedis arteries are 
detected using intersecting tangent methods (similar to SphygmoCor method). Time 
differences of upstroke points between two different sites are then used to calculate 
regional PWV values. Four different regional PWV values can be derived: Carotid to 
Radial (CR), Carotid to Femoral (CF) Carotid to Dorsais pedis (CD) and Femoral to 
Dorsalis pedis (FD). The simultaneously measured pulse wave velocites with their 
pressure waveforms using PP-1000 systems are illustrated in Figure 2.7.
Figure 2.7 Simultaneous PWV recordings displayed on screen of PP-1000 system.
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The reproducibility of the PP-1000 system for measuring PWV has not been assessed 
against other systems. It has therefore been compared to the SphymoCor system in the 
following Chapter. In addition, measurement of AIx has been compared between the 
SphygmoCor system and the Goan21A.
2.4 Statistics and power calculations
In order to test the study hypothesis, power calculations were performed to ensure the 
correct number of subjects to be recruited:
N = 10.5 x 1.172 x 2
0.72
N = 59 people
10.5 = Constant used to obtain a significance level of 0.05 with a power of 0.90,
1.17 = SD from repeated measure aortic PWV, 0.7 = a clinically significant difference 
in aortic PWV.
Based on a standard deviation of differences between repeated measurements of aortic 
pulse wave velocity of 1.17 metre/second (taken from the Anglo Cardiff 
Collaboration Trial, ACCT study database of over 2500 subjects), 59 subjects in each 
group will provide a 90% chance of detecting a 0.7 metres/second difference in 
aPWV between the groups, at the 0.05 significance level. A difference observed 
below 0.7 metres/second is unlikely to be clinically or physiologically meaningful.
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PULSE WAVE VELOCITY AND AUGMENTATION INDEX, 
MEASURED BY THE PP-1000/GAON21A SYSTEM AND 
COMPARED TO THE SPHYGMOCOR SYSTEM
(STUDY 1)
3.1 Introduction
Large arterial stiffness is a major independent risk factor for cardiovascular disease 34‘ 
36. Large artery stiffness is a consequence of premature vascular ageing due to 
cardiovascular risk factors such as hypertension , diabetes and 
hypercholesterolemia 74. The aetiology and progression of these changes are due to 
structural and functional alterations (see Figure 1.7, Chapter 1). Clinically overt 
atheromatous disease may be preceded by increased arterial stiffness 161, thus, making 
early detection extremely important in the diagnosis and management of impending 
cardiovascular disease. Recognition of this has lead to the development of a number 
of different techniques to measure arterial stiffness 10°. The majority of published 
studies have validated and used the SphygmoCor system to perform pulse wave 
analysis and measure carotid-femoral PWV 16,162,163. This study therefore examines 
the reproducibility of the PP-1000/Gaon21A system (Hanbyul Meditech, Korea) and 
compares it with the SphymoCor system as one of the most widely used and “gold 
standard” method for measuring aortic stiffness100. This is important, as subsequent 
studies will use the PP-1000 to measure PWV in the femoral-dorsalis pedis vascular 
bed.
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3.2 Methodology
3.2.1 Subject Recruitment
19 subjects (10 healthy participants, aged 24 ± 3 and 9 Type-2 diabetics, aged 50 ± 7 
years) participated in the study. Participants were recruited for the study, as part of a 
self-referral risk factor clinic, in the Heath Hospital, Cardiff. Identical protocols were 
performed on each of the participants.
3.2.2 Blood Pressure Measurement
BP was recorded after ten minutes rest at the brachial artery of the dominant arm 
using a validated semi-automated oscillometric device and according to BHS 
guidelines 156. All haemodynamic measurements were made in a quiet, temperature- 
controlled room of 22°C. Duplicate readings were performed on each occasion, and an 
average recorded.
Table 3.1. General group characteristics (N=19)
Mean ± SD Min - Max
Age (yr) 40 ± 18 21-67
Height (cm) 177 164-192
Weight (kg) 78 57-115
BMI (kg/m2) 24 20-32
SBP (mmHg) 119 94 - 144
DBP (mmHg) 72 55-89
MBP (mmHg) 103 87-122
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
MBP, mean blood pressure
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3.2.3 Pulse Wave Analysis (PWA) Using SphygmoCor
PWA was performed using the SphygmoCor system as described in Chapter 2. For 
the purpose of this study, only AIx was recorded for comparison with Gaon21 A.
3.2.4 Pulse Wave Velocity (PWV) Using SphygmoCor
Palpation of the radial, carotid, femoral and dorsalis pedis pulse were located and 
marked before the distance to each site was measured from the sternal notch, using a 
measuring tape. In brief, carotid radial, carotid femoral and carotid dorsalis pulse 
wave velocities were measured sequentially as the time taken for the pulse to travel 
from a three lead ECG-gated signal to the first upstroke of the pulse wave at the 
carotid, radial, femoral and dorsalis pedis site. A simple 3 lead ECG was attached in 
order for the pulse traces obtained from the tonometer to be gated against the R wave 
of the ECG and determine pulse wave transit time (velocity = distance/Atime), which 
along with the measured distances, allowed PWV to be calculated. Two separate 
readings were obtained, with approximately two minutes duration between each 
measurement, for each regional segment (e.g. CR PWV). Waveforms and readings 
were assessed visually to ensure good quality pulse traces and minimize any user 
induced artefacts.
Upon completion of all the measurements using the SphgymoCor system, the ECG 
was removed and the PP-1000 device was set up.
3.2.5 Pulse Wave Analysis (PWA) Using Gaon21A
Pulse wave analysis was performed and AIx measured in the same way as described 
in Chapter 2.
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At the screening visit, participants proceeded to lie in a supine position for at least ten 
minutes before any other measurements were obtained. Duplicate supine blood 
pressure readings were obtained using the Omron device before PWV measurements 
obtained.
3.2.6 Pulse Wave Velocity (PWV) Using PP-1000
Forceps were placed over the subject’s arms to obtain an ECG signal, and a PCG 
sensor placed over the chest. Semi conductor pressure sensors were then attached to 
each arterial site using velcro straps, illustrated in Chapter II. In similar fashion to the 
SphygmoCor system, PWV was measured as the time taken for the pulse to travel 
from the R wave of the simultaneously recorded ECG to the upstroke of the pulse 
wave at the site of assessment. As mentioned earlier, the difference between the two 
systems is that the PP-1000 system records all regional PWV measurements 
simultaneously, compared to sequential readings of the SphygmoCor.
Once all the Velcro straps and pressure sensors are applied over all the sites, recording 
of each regional PWV was obtained.
Measurements were repeated and assessed visually to ensure a good quality trace was 
recorded. Previously measured supine blood pressure and anatomical distances were 
used for the PP-1000 system.
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3.2.7 Statistical Analysis
Data were analysed using Bland-Altman plots and reproducibility was expressed in 
terms of the mean difference ± SD between paired measurements. Paired sample t- 
tests were used to test for significant differences where appropriate and a P-value of 
<0.05 was accepted as significant.
3.3 Results
3.3.1 Comparison o f PW V Using Three Systems
Table 3.2 presents the results obtained from the SphygmoCor, PP-1000 and Gaon21 A 
systems. Results for each regional PWV, AIx and heart rate are shown as mean ±SD. 
A P-value of <0.05 was considered as significant. CF PWV measured by the 
SphygmoCor system and the PP-1000 was significantly different (7.2 ± 2.1 m/s 
compared to 6.4 ± 1.8m/s respectively (P=0.022)). CR PWV was also significantly 
different between the SphygmoCor and the PP-1000 (7.8 ± l.lm /s compared to 7.0 ±
1.6 m/s respectively (P=0.036)). However, results for the Carotid-Dorsalis pedis PWV 
(CD PWV) and FD PWV were not significantly different between the SphygmoCor 
and the PP-1000 systems (NS).
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Table 3.2. Differences observed between SphygmCor and the PP-1000 or the 
Goan 21A systems
SphygmoCor PPlOOO/Gaon 21A P-value
Carotid-Femoral PWV (m/s) 7.2 ±2.1 6.4 ±1.8 0.022
Carotid-Radial PWV (m/s) 7.8 ±1.1 7.0 ±1.6 0.036
Carotid-Dorsalis-pedisPWV (m/s) 7.3 ±1.1 6.9 ± 1.1 0.065
Femoral-Dorsalis-pedis PWV (m/s) 7.6 ±1.0 7.9 ±2.1 0.34
Supine Heart Rate (bpm) 59.5 ± 8.7 59.9 ±9.1 0.842
Seated Augmentation Index (%) 15.1 ±9.4 14.5 ± 7.9 0.645
Using Bland-Altman plots, within observer variation for the CF PWV reading for PP- 
1000 showed a SD of 0.02m/s, (Figure 3.1). Similar results were obtained for within 
observer variability for the SphymoCor system (SD 0.02 m/s), demonstrating a high 
degree of reproducibility for measurements of CF PWV within the two systems.
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Figure 3.1. W ithin observer variation o f CF PW V  for the PP-1000 apparatus 
shown here as a Bland Altm an plot.
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On the next page, between-apparatus variability was also assessed using Bland- 
Altman plots. Bland-Altman plots were constructed for differences between systems 
using (a) CF PWV and (b) FD PWV (Figures 3.2a and b). CF PWV showed a SD of
1.5 m/s between systems. The between system variability for the FD PWV showed a 
SD of 1.9 m/s (see Table 3.3). We examined correlation coefficients for the two 
systems. Between systems, the CF PWV showed a correlation coefficient of 0.76. 
When measuring FD PWV the observed correlation coefficient was 0.47.
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Figure 3.2. Bland-Altman plots demonstrate differences observed between 
SphygmoCor and PP-1000 when measuring CF PWV and FD PWV.
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= Non-diabetic controls, Q  = Diabetic individuals.
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Table 3.3. Between apparatus differences (PP-1000 and Gaon21A versus 
SphygmoCor) for each parameter throughout the entire group.
Mean SD r value P-value
Carotid -  Femoral (m/s) 0.8 1.5 0.76 <0.001
Carotid -  Radial (m/s) 0.8 1.4 0.52 0.023
Carotid -  Dorsalis (m/s) 0.4 0.9 0.65 0.003
Femoral -  Dorsalis (m/s) 0.4 1.9 0.47 0.041
Aix (%) 0.6 5.4 0.82 <0.001
3.4.2 Comparison o f A Ix  Using SphygmoCor and Gaon21A
A comparison was also performed between the SphygmoCor system and the 
Gaon21A for AIx. Figure 3.3 on the next page illustrates the variation observed 
between the two systems, as demonstrated in a Bland-Altman plot. A non-significant 
difference of P=0.645 was observed after completion of a paired sample t-test, 
suggesting there is no significant difference observed between the two apparatus 
involved. A correlation coefficient of r= 0.82, with mean±SD of 0.6±5.4 was also 
observed.
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Figure 3.3. Bland-Altm an plots describe differences observed between 
Sphygm oC or and Gaon 21A, when m easuring A ix.
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3.4 Discussion
Findings from this study show that there is a between apparatus variation of 1.4m/s 
between the SphygmoCor system and the PP-1000 device when measuring CF PWV. 
The results of this study do however show that there is a significant difference 
observed between the means of each apparatus when assessed using a paired sample t- 
test.
However, correlation coefficients (shown in Table 3.3) demonstrate the relationship 
observed between CF PWV results. An r value of 0.76, with a P value of <0.001, 
suggests that there is a good relationship between apparatus. See Table 3.3 for details
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of all the regional correlations observed in PWV and Aix for the two devices under 
investigation.
FD PWV was also assessed in order to assess the reproducibility between apparatus. 
Again, Bland-Altman plots were used to demonstrate the overall reproducibility of the 
two devices used. A significant correlation was observed between the two systems 
(r=0.47, P = 0.041). A paired sample t-test was used to assess the differences in means 
between the two apparatus. No significant difference was observed between devices.
Previous studies have compared SphygmoCor to another similar apparatus devised for 
measuring PWV. The study described by Milleasseau et al, 2005, compares the 
Complior system, which measures PWV simultaneously, similar to that of the PP- 
1000, to the SphygmoCor 164. This study demonstrated a variability of 1.07 m/s 
between the SphygmoCor and the Complior, which is in broad agreement with the 
current study comparing the SphymoCor system to the PP-1000. Potential reasons for 
this agreement are that the two systems used the same intersecting tangent algorithms 
to identify the foot of the pulse waveform. However, the differences observed 
between comparisons of the Complior and PP-1000 with the SphygmoCor system 
may be due to differences in the pressure transducers used to record the arterial 
waveforms.
In the current study, some degree of variability may be due to the fact that the 
SphygmoCor system measures PWV sequentially, whereas the PP-1000 measures 
PWV simultaneously. However, the fact that the two systems exhibit the same within 
observer variation, make this unlikely.
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Possible limitations of the study: The femoral artery pulse waveform can sometimes 
be difficult to record using the PP-1000 system due to the design of the apparatus. 
Having the transducer applied over the artery at the femoral site by a Velcro strap 
sometimes does not allow enough pressure to obtain a clear waveform in overweight 
subjects, due to increased adiposity. Therefore, inaccurate femoral pulse waveforms 
may have resulted in some degree of variation when recording CF PWV and FD PWV 
when using the PP-1000. However, the average BMI of the group investigated was 
not considered obese, therefore minimal obstruction in obtaining a clear femoral 
waveform would have been witnessed.
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DIABETES, ETHNICITY AND ARTERIAL STIFFNESS 
(STUDY 2)
4.1 Introduction
Diabetes mellitus is a major risk factor in cardiovascular disease (CVD) with CVD 
being the most common cause of death in patients with type-2 diabetes mellitus 165. 
The increased risk of CVD is due in part to clustering of other risk factors such as 
obesity, hypertension and dyslipidaemia with type-2 diabetes.
However, this does not explain all the risk. Indeed, diabetics without additional risk 
factors have increased cardiovascular risk compared with non diabetics. Arterial 
stiffness is emerging as an independent risk factor for CVD 34'36 and this has lead a 
number of investigators to examine the relationship between diabetes and arterial 
stiffness. Studies have shown increased arterial stiffness in both type-1 and type-2
c c  n c  nc.
diabetics compared with controls ’ ’ .
These findings were confirmed in the large population based study Atherosclerosis 
Risk In Communities (ARIC) study, which used carotid intima media thickness as a 
measure of arterial stiffness and demonstrated increased arterial stiffness in patients 
with type 2 diabetes mellitus. Investigators also showed a positive correlation 
between glucose levels and arterial stiffness and an inverse relationship between
7 r
insulin and arterial stiffness
Recent studies have extended these findings, showing PWV to be “a powerful 
independent predictor of later mortality across an entire spectrum of glucose 
tolerance, with or without type-2 diabetes” .
Although most studies have demonstrated an increased Aix in diabetics compared to 
non-diabetics 55,87,88 a recent study by Lacy et al in 2004 89 failed to show any 
differences in Aix between diabetics and controls although there was a significantly
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higher aortic PWV in the diabetics. Other studies using carotid intima media 
thickness (CIMT) as a measure of arterial stiffness have shown no differences 
between diabetic subjects and controls 86,166. Suggesting that diabetes may have a 
differential effect on large arteries such as the aorta and carotid. Interestingly, an 
interventional study by Esposito et al 2004 illustrated that a reduction in CIMT was 
associated with a reduction in postprandial hyperglycaemia but not fasting 
hyperglycaemia in diabetics94. Furthermore, recent data suggest that in type-2 
diabetics, central artery stiffening is more pronounced than that of the peripheral 
arteries 83. Similar findings were reported by Cameron et al, in 2002, where they 
showed a differential stiffening of the central and peripheral arteries in diabetics 
compared to controls 84.
Mortality and stroke rates of South Asians are 1.5 times that of the general population 
in the UK 167 and glucose intolerance, central obesity, fasting triglycerides and insulin 
are all elevated compared to Europeans. Interestingly, although South Asians have a 
similar prevalence of Ischaemic Heart Disease (IHD) to Caucasians, their prevalence 
of peripheral vascular disease (PVD) is considerably lower 145. This remains a 
consistent finding even in the presence of classical risk factors such as diabetes . A 
recent study (Chaturvedi et al in 2002), showed that South Asians have a lower 
incidence of amputation compared to Europeans and that this was related to a lower 
prevalence of neuropathy and PVD compared to Caucasians 147.
The reasons that PVD is less prevalent in South Asians remains unclear. However, if 
increased arterial stiffness predisposes to atherogenesis, then a plausible explanation 
would be that the femoral vascular bed of South Asains exhibits a lower rate of age 
related stiffening than that of Caucasians.
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In order to investigate these possibilities further, this study has examined arterial 
stiffness in a number of vascular beds by measuring carotid-femoral, carotid-radial 
and femoral-dorsalis pedis PWV in South Asians and Caucasians, with and without 
diabetes.
Aims and Objectives
In this chapter, the results of four studies undertaken to address the following 
hypothesis are presented.
(Study 2a) Comparison of arterial stiffness in all subjects with type-2 diabetes 
and matched controls.
(Study 2b) Comparison of arterial stiffness in Caucasian type-2 diabetics and 
matched controls.
(Study 2c) Comparison of arterial stiffness in non diabetic South Asians and 
Caucasians, and
(Study 2d) Comparison of arterial stiffness in type-2 diabetics of South Asian and 
Caucasian origin.
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Table 4.0. Diabetes and Arterial Stiffness.
Reference Population Measurements Main Finding
ARIC [75] 4,700 T-2 diabetics Carotid artery 
stiffness
+’ve association 
between diabetes 
and diabetes
Hoorn [76] 1,193 with 
normoglycaemia, 
impaired glue, 
regulation or 
diabetes
CIMT Diabetics had a sig. 
relationship with 
CIMT
Hoorn [76] 208 T-2 diabetics Pulse Pressure +’ve association 
between PP and 
CV mortality
Finne Dianne [78] 2,988 T-l diabetics 
5,486 non-diabetics
Pulse Pressure Sig. higher PP in 
the T-l diabetics
Wahlqvist [80] Small numbers. 
<100.
Aorto-iliac PWV 
(Ultrasound)
Higher aorto-iliac 
PWV in diabetics 
compared to 
controls
Taniwaki [82] Small numbers. 
<100.
Aortic PWV Higher aPWV in 
diabetics compared 
to controls
Cameron [84] Small numbers. 
T-2 diabetics and 
controls
PWV of central and 
peripheral arteries
Central arteries age 
at an accelerated 
rate in diabetics 
compared to 
controls
Brooks [87] [88] Small numbers 
<100. T-l, T-2 
diabetics and 
controls
AIx and central 
pressure
Higher AIx and 
central pressure in 
diabetics compared 
to controls
Wilkinson [55 ] Small numbers. 
<100. T-l diabetics 
and controls
AIx, Tr AIX and Tr were 
greater in diabetics 
compared to 
controls.
Emoto [85] and 
Kool [86]
Small numbers. 
Diabetics and 
controls
Carotid, brachial and 
femoral. Ultrasound 
and SI.
No difference 
between diabetics 
and controls
Kool [86] Small numbers. 
Diabetics and 
controls
CF PWV No difference 
between diabetics 
and controls
Lacey [89] Small numbers. 
<100 T-l, T-2 
diabetics and 
controls
AIx and CF PWV CF PWV was >in 
the diabetics 
compared to the 
controls, however, 
AIx was not.
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4.2 Methodology
4.2.1 Recruitment o f Participants
Diabetic volunteers were recruited from diabetic outpatient clinics in the Heath 
Hospital and Llandough Hospital, in South Wales. An advertisement was written for 
the health section of the South Wales echo (a local news paper), to increase people’s 
awareness of the prevalence of diabetes and cardiovascular disease within the South 
Wales area, particularly in the South Asian community, whilst advertising for this 
study. In addition, a telephone contact number was provided with the advertisement 
in the paper for those individuals interested in taking part or who wanted further 
information. South Asian volunteers were recruited from the general population, via 
links with the Asian professional association and the Barefoot Health-Workers 
Project, in Cardiff. A family, general health promotion day was held during the year 
to once again, increase awareness of diabetes and CVD in South Wales and especially 
in the South Asian community. From this event, we also promoted our study. Due to 
ethical / religious issues involved in the part-removal of clothing during the study, 
only male volunteers were chosen for this study.
4.2.2 Study Population
347 healthy, male volunteers, aged 20-70, mean age 39.56±12.3 years, of South Asian 
(N=65) and Caucasian (N= 282) ethnicities, were recruited for the study. Participants 
were generally from the local population of Cardiff city and the surrounding areas. 
Participants free from any overt cardiovascular disease were recruited for the study. 
85 individuals with known type-2 diabetes, aged between 40-70, mean age 58.91±8.3 
years, of South Asian (N=36) and Caucasian (N= 49) ethnicities, participated in the 
study.
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A detailed personal medical and family medical history questionnaire was completed. 
Subjects receiving cardiovascular related medications were also excluded from the 
control group. Ethical approval was obtained from the local research ethics committee 
(LREC), our institution’s research and development department (R&D) and 
performed in accordance with the declaration of Helsinki. Informed consent was also 
obtained from each participant before any measurements were undertaken.
4.2.3 Data Collection
Participants were invited to attend an initial screening visit, lasting approximately one 
hour. Written informed consent was obtained from all participating subjects, before 
answering questions about their personal and family medical history. Height, weight, 
waist and hip circumferences were measured using standard methods.
4.2.4 Blood Pressure Measurement (Seated and Supine)
Blood pressure was recorded as stated in chapter 2, section 2.3.1. Duplicate readings 
were performed on each occasion, to rule out any discrepancies, and the average was 
used in subsequent analysis.
4.2.5 Assessment o f Arterial Stiffness
Arterial stiffness was compared between diabetic subjects and age sex matched 
controls. In addition, arterial stiffness was also assessed in South Asians with type 2 
diabetes and compared to Caucasian diabetic subjects. Arterial stiffening was also 
compared across different vascular beds in non-diabetic South Asians and Caucasians 
Arterial stiffness was assessed using SphygmoCor and PP-1000 systems, which uses 
the applanation tonometry principle, described in detail in Chapter 2, section 2.3.
Chapter 4. Diabetes, Ethnicity and Arterial Stiffness
In order to assess Femoral-Dorsalis PWV (FD PWV), the PP-1000 (Hanbyul 
Meditech Co., Korea) was used PWV was recorded based on the measurements of 
ECG and pulse waves from four different sites (carotid, femoral, radial and dorsalis 
pedis) simultaneously.
4.2,6 Data Analysis and Statistics
Data was analysed using SPSS for Windows version 11.5 (SPSS Inc., Chicago, 
Illinois). Independent sample t-test were used to test for significance and compare 
means of each group. All values represented as mean ± SD, and a P value of <0.05 
was considered significant. In order to test the study hypothesis, power calculations 
were performed to ensure the correct number of subjects to be recruited. See 
calculation in Chapter 2, section 2.4.
*
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4.3 Results
The following sections describe the results of the four studies and presented as Tables
4.1 to 4.8 and Figures 4.1 to 4.4.
4.3.1, Comparison o f arterial stiffness in subjects with type - 2 diabetes and 
matched controls. (Study 2a)
Three hundred and sixty two men volunteered for this study. Two hundred and 
seventy eight were healthy controls and eighty four were type-2 diabetics. Seated and 
supine haemodynamic measurements for the two groups are shown in Tables 4.1 and
4.2.
Seated central pressures were not significantly different between groups. However, 
supine CSBP and CMAP were significantly different in the diabetic group compared 
to controls.
Supine PMAP was not significantly different between the two groups. However, there 
was a significant difference in PPP. Supine AIx was also lower in the diabetic group 
compared to the healthy controls but when HT and HR and PMAP were adjusted for, 
this difference was found to be non significant.
CF PWV was found to be higher in the diabetic group compared to the healthy 
controls. However, there were no significant differences in either CR or FD PWV. 
(See Figure 4.1)
4
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Table 4.1. Group characteristics and seated vascular haemodynamics between 
healthy controls and diabetics.
Healthy Controls 
(N=278)
Diabetics
(N=84) P  Value
Group Characteristics
Age (years) 59±11 59±8 NS
BMI (Kg/m2) 26.9±3.9 30.0±5.0 <0.001
Height (m) 1.75±0.07 1.69±0.07 <0.001
Vascular Haemodynamics (Seated)
PSBP (mmHg) 135±18 141±16 0.013
PDBP (mmHg) 82±9 83±11 NS
PMAP (mmHg) 100±13 102110 NS
PPP (mmHg) 53±13 58114 0.006
CSBP (mmHg) 123±17 125114 NS
CDBP (mmHg) 83±11 84110 NS
CMAP (mmHg) 97±12 98110 NS
CPP (mmHg) 40±12 40111 NS
AIx (%) 20±11 1519 <0.001
AIx (HT & HR adjusted) 20±9 1818 NS
HR (bpm) 68±11 78112 <0.001
AP (mmHg) 9±6 715 0.013
Tr (ms) 143±14 13516 <0.001
0
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Table 4.2. Group characteristics and supine vascular haemodynamics between 
healthy controls and diabetics.
Healthy Controls 
(N=278)
Diabetics
(N=84) P  Value
Vascular Haemodynamics (Supine)
PSBP (mmHg) 133±20 134114 NS
PDBP (mmHg) 79±9 7618 0.003
PMAP (mmHg) 97±12 9518 NS
PPP (mmHg) 53±14 58113 0.01
CSBP (mmHg) 123117 120113 NS
CDBP (mmHg) 80110 7718 0.003
CMAP (mmHg) 94112 9118 0.009
CPP (mmHg) 42111 43111 NS
AIx (%) 25110 2119 0.003
AIx (corrected) 24110 2218 NS
HR (bpm) 64+9 72110 <0.001
AP (mmHg) 1116 916 0.026
Tr (ms) 144115 141111 0.02
Tr (corrected) 145113 140111 0.003
CF PWV (m/s) 8.611.4 10.313 <0.001
CFPWV (corrected) 8.611.3 10.412.9 <0.001
CR PWV (m/s) 9.012.3 8.811.2 NS
CRPWV (corrected) 9.211.9 9.011.1 NS
FD PWV (m/s) 10.212.2 9.711.8 NS
FDPWV (corrected) 10.812.0 (N=66) 10.111.7 (N=33) NS
4
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Figure 4.1. Differences in regional vascular stiffness between all healthy controls 
and all diabetic participants.
14 1 
13 -
12  -
NS
NS
*P<0.001
PWV (m/s) 9 HHC 
■ DIABS
CF PWV CR PWV FD PWV
PWV: Pulse wave velocity; CF PWV: Carotid femoral pulse wave velocity; CR 
PWV: Carotid radial pulse wave velocity; FD PWV: Femoral dorsalis pulse wave 
velocity; HC: Healthy controls; DIABS: type-2 diabetics.
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4.3.2 Comparison o f arterial stiffness in Caucasian type-2 diabetics and matched 
controls. (Study 2b)
Three hundred and thirty one male Caucasian volunteers participated in this study. 
Forty nine had type 2 diabetes and two hundred and eighty two were non-diabetic 
controls. Haemodynamic parameters in the two groups are shown in Tables 4.3 and 
4.4.
There was no significant difference in PMAP between the groups (Table 4.3). 
However seated PPP was significantly different (HC:53±13 versus DC:59±13 mmHg, 
P=0.003). This was mainly due to the significantly higher PSBP of the Diabetic 
group.
No significant differences were observed in central blood pressures in the seated or 
supine position between groups.
Seated AIx was also significantly different, with the diabetic group having a lower 
AIx. However, when seated HR and HT were adjusted for, there was no difference 
between groups (19±10 versus 17±9 (%), P=0.116).
Results for supine BP were similar with no differences in PMAP but a significant 
increase in supine PPP in the diabetic group (Table 4.4). There were no differences in 
Supine AIx and this remained non significant after adjusting for HT, supine HR and 
supine PMAP.
After adjustment for age and supine PMAP, CF PWV was significantly greater in the 
diabetics relative to the controls (HC:8.5±1.5 versus DC:10.7±3.3 m/s, P<0.001). No 
differences were observed in CR PWV between the groups. However, after 
adjustment for age and supine MAP, FD PWV was higher in the non diabetic subjects 
(11.1 ±1.9 versus 10.1 ±2 m/s, P=0.047). The differences in regional arterial stiffness 
between the two groups are illustrated graphically in Figure 4.2.
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4.3. Group characteristics and seated vascular haemodynamics between healthy 
Caucasians and diabetic Caucasians.
Healthy Caucasians Diabetics 
(N=282) (N=49) P  Value
Group Characteristics
Age (years) 58±12 59±7 NS
BMI (Kg/m2) 26.9±4.0 32.0±5.0 <0.001
Height (m) 1.75±0.07 1.71 ±0.07 <0.001
Vascular Haemodynamics (Seated)
PSBP (mmHg) 135±18 143±16 0.006
PDBP (mmHg) 82±11 83±10 NS
PMAP (mmHg) 100±13 103±10 NS
PPP (mmHg) 53±13 59±13 0.003
CSBP (mmHg) 122±17 125±15 NS
CDBP (mmHg) 83±11 84±10 NS
CMAP (mmHg) 96±12 98±11 NS
CPP (mmHg) 39±12 41±11 NS
AIx (%) 20±12 15±9 0.007
AIx (HT & HR adjusted) 19±10 17±9 NS
HR (bpm) 69±11 77±12 <0.001
AP (mmHg) 9±6 7±5 NS
Tr (ms) 144±13 135±6 <0.001
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Table 4.4. Group characteristics and supine vascular haemodynamics between 
healthy Caucasians and diabetic Caucasians.
Healthy Caucasians Diabetics
(N=282)___________ (N=49)____________ P  Value
Vascular Haemodynamics (Supine)
PSBP (mmHg) 132±19 137±13 NS
PDBP (mmHg) 79±10 76±7 NS
PMAP (mmHg) 97±12 96±8 NS
PPP (mmHg) 53±14 60±10 <0.001
CSBP (mmHg) 122±17 122±12 NS
CDBP (mmHg) 80±10 77±8 NS
CMAP (mmHg) 94±12 92±8 NS
CPP (mmHg) 42±11 44±9 NS
AIx (%) 24±11 21±9 NS
AIx (corrected) 24±9 23±8 NS
HR (bpm) 64±9 70±10 <0.001
AP (mmHg) 11±6 9±5 NS
Tr (ms) 146±17 142±11 0.022
Tr (corrected) 146±15 141±11 0.009
CF PWV (m/s) 8.5±1.5 10.7±3.4 <0.001
CFPWV (corrected) 8.7±1.3 10.9±3.2 <0.001
CR PWV (m/s) 8.9±2.4 9.2±1.1 NS
CR PWV (corrected) 8.9±1.8 9.0±1.1 NS
FD PWV (m/s) 10.4±2.2 9.8±2.1 NS
FDPWV (corrected) 11.1±1.9 (N=33) 10.1 ±2.0 (N=66) 0.047
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Figure 4.2. Differences in regional arterial stiffness between the healthy 
Caucasians and diabetic Caucasians.
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NS
* P < 0.05 
** P< 0.001
CFPWV CRPWV FDFWV
PWV: Pulse wave velocity; CF PWV: Carotid femoral pulse wave velocity; CR 
PWV: Carotid radial pulse wave velocity; FD PWV: Femoral dorsalis pulse wave 
velocity; HC: Healthy controls; DIABS: type-2 diabetics.
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4.3.3 Comparison o f arterial stiffness in non-diabetic South Asians and 
Caucasians. (Study 2c)
In total, two hundred and seventy nine men participated in this analysis. 214 
Caucasians and 65 South Asians. Table 4.5 shows the general group characteristics 
and seated vascular haemodynamics, whilst Table 4.6 illustrates the differences 
between the groups in supine position. Seated peripheral SBP, DBP, MAP, and PP 
were all significantly higher in the Caucasians relative to the South Asians (Table 
4.5). Furthermore, only CPP was significantly higher in the Caucasian groups, both in 
the seated and supine position.
For supine BP there were no significant differences in PMAP or PDBP. However, 
there were significant differences in PPP and PSBP which were higher in the 
Caucasian group. After adjustment for PMAP, HR and HT no significant differences 
were observed in seated or supine AIx between groups (Table 4.6). Since there was a 
difference in PMAP between groups, PWV measurements were adjusted for age and 
PMAP. CF PWV and FD PWV were both significantly lower in the South Asians. 
However, in contrast, CR PWV was lower in the Caucasian group. (See Figure4.3).
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Table 4.5. Group characteristics and seated vascular haemodynamics between 
healthy South Asians and healthy Caucasians.
Healthy S. Asians 
(N=65)
Healthy Caucasians 
(N=214) P  Value
Group Characteristics
Age (years) 40±10 39114 NS
BMI (Kg/m2) 26.913.8 25.913.9 NS
Height (m) 1.7110.07 1.7510.07 <0.001
Vascular Haemodynamics (Seated)
PSBP (mmHg) 128114 133117 0.015
PDBP (mmHg) 8719 84112 0.035
PMAP (mmHg) 10118 99113 0.023
PPP (mmHg) 41111 50111 <0.001
CSBP (mmHg) 117113 118117 NS
CDBP (mmHg) 8819 85112 NS
CMAP (mmHg) 98110 96113 0.279
CPP (mmHg) 2918 3319 0.002
AIx (%) 17112 9115 <0.001
AIx (corrected) 13111 11114 NS
HR (bpm) 72111 69113 NS
AP (mmHg) 615 517 0.043
Tr (ms) 145113 147113 NS
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Table 4.6. Group characteristics and supine vascular haemodynamics between 
healthy South Asians and healthy Caucasians.
Healthy S. Asians 
(N=65)
Healthy Caucasians 
(N=214) P  Value
Vascular Haemodynamics (Supine)
PSBP (mmHg) 123±13 129115 0.004
PDBP (mmHg) 78±8 76112 NS
PMAP (mmHg) 93±9 93112 NS
PPP (mmHg) 45±10 53110 <0.001
CSBP (mmHg) 111±12 113115 NS
CDBP (mmHg) 79±9 77112 NS
CMAP (mmHg) 90±9 89113 NS
CPP (mmHg) 32±7 3617 <0.001
AIx (%) 19±12 11115 <0.001
AIx (corrected) 13±12 10114 NS
HR (bpm) 66±10 64111 NS
AP (mmHg) 6±5 416 0.015
Tr (ms) 149±10 157119 <0.001
Tr (corrected) 149±10 158117 <0.001
CF PWV (m/s) 7.3±1.4 8.011.4 <0.001
CFPWV (corrected) 7.2±1.2 8.011.3 <0.001
CR PWV (m/s) 8.3±1.2 7.512.2 <0.001
CRPWV (corrected) 8.2±1 7.011.4 <0.001
FD PWV (m/s) 9.5±1.6 10.012.6 NS
FDPWV (corrected) 9.411.6 (N=43) 10.512.4 (N=50) 0.019
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Figure 4.3. Differences in regional arterial stiffness between healthy South 
Asians and healthy Caucasians.
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PWV: Pulse wave velocity; CF PWV: Carotid femoral pulse wave velocity; CR 
PWV: Carotid radial pulse wave velocity; FD PWV: Femoral dorsalis pulse wave 
velocity; HA: Healthy South Asians; HC: Healthy Caucasians.
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4.4 Comparison o f arterial stiffness in diabetic South Asians and diabetic 
Caucasians (Study 2d)
Eighty five subjects took part in this study. Thirty six were South Asians with type-2 
diabetes and forty nine Caucasian diabetics. The vascular haemodynamic data are 
presented as Tables 4.7 and Table 4.8 for both seated and supine positions 
respectively.
No significant differences were observed in any component of blood pressure, either 
seated or supine, central or peripheral, apart from supine PSBP which was higher in 
the diabetic Caucasians. Again, after adjustment for PMAP, HR and HT there were 
no significant differences in AIx, either seated or supine between the groups. Finally, 
there were no significant differences between CF PWV, CR PWV or FD PWV 
between the groups.
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Table 4.7. Group characteristics and seated vascular haemodynamics between 
diabetic South Asians and diabetic Caucasians.
Diabetic S. Asians 
(N=36)
Diabetic Caucasians 
(N=49) P  Value
Group Characteristics
Age (years) 58±9 5917 NS
BMI (Kg/m2) 27.2±3.5 32.014.9 <0.001
Height (m) 1.68±0.07 1.7110.07 NS
Duration of Diab (yrs) 12.5±11 9.718 NS
No. Microvasc Comp 0.5±0.8 0.510.7 NS
No. CV Med 1.611.4 2.411.7 0.04
Vascular Haemodynamics (Seated)
PSBP (mmHg) 139114 143116 NS
PDBP (mmHg) 83110 83110 NS
PMAP (mmHg) 10219 103110 NS
PPP (mmHg) 56115 59113 NS
CSBP (mmHg) 124112 125115 NS
CDBP (mmHg) 8519 84110 NS
CMAP (mmHg) 9818 98111 NS
CPP (mmHg) 40112 41111 NS
AIx (%) 1619 1519 NS
HR (bpm) 79112 77112 NS
AP (mmHg) 716 715 NS
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Table 4.8. Group characteristics and seated vascular haemodynamics between 
diabetic South Asians and diabetic Caucasians.
Diabetic S. Asians 
(N=36)
Diabetic Caucasians 
(N=49) P  Value
Vascular Haemodynamics (Supine)
PSBP (mmHg) 130±15 137113 0.042
PDBP (mmHg) 75±8 7618 NS
PMAP (mmHg) 94±8 9618 NS
PPP (mmHg) 55±15 60110 NS
CSBP (mmHg) 117113 121112 NS
CDBP (mmHg) 7718 7718 NS
CMAP (mmHg) 9019 89113 NS
CPP (mmHg) 40113 4419 NS
AIx (%) 20110 2119 NS
AIx (corrected) 2218 2117 NS
HR (bpm) 73110 71110 NS
AP (mmHg) 916 1015 NS
Tr (ms) 140112 141111 NS
Tr (corrected) 139111 142111 NS
CF PWV (m/s) 9.812.6 10.713.4 NS
CFPWV (corrected) 8.512.2 8.712.8 NS
CR PWV (m/s) 8.411.1 9.211.1 0.003
CRPWV (corrected) 8.111 8.611.0 NS
FD PWV (m/s) 9.611.3 9.812.1 NS
FDPWV (corrected) 9.711.3 (N=31) 9.811.9 (N=35) NS
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4.4 Discussion
The major positive findings from this series of experiments are, that in agreement 
with previous studies, subjects with type 2 diabetes had increased CF PWV when 
compared to matched non-diabetic controls. When Caucasians with type-2 diabetes 
were compared to matched Caucasian control subjects with diabetes they also 
exhibited increased CF PWV. In agreement with the original hypothesis that South 
Asians would have a lower FD PWV than Caucasian controls we were indeed able to 
demonstrate this. However, interestingly there were no differences in PWV in any of 
the vascular beds when comparing South Asian diabetics with Caucasian diabetics. 
These findings are discussed in more detail below.
Study 2a: Comparison o f arterial stiffness in all subjects with type-2 diabetes and 
matched controls
This study demonstrated an increased CF PWV between diabetic subjects and 
controls but no differences in CR or FD PWV which is in agreement with previous
o n
studies * showing that there is preferential stiffening of central arteries such as the 
aorta relative to more peripheral arteries such as the brachial or femoral. The reasons 
for this remain unclear. However, it may be that diabetes increases breakdown and 
fragmentation of elastin which would account for its preferential effect on large 
arteries as they have a higher elastin component. Furthermore, the current study 
demonstrated no significant differences in AIx between diabetics and controls.
c c  o o
Although this is in disagreement with some previous studies ’ a recent study by 
Lacy et a l89 despite demonstrating increased CF PWV between diabetics and controls 
also failed to show differences in AIx. A potential explanation for this is the age of 
the subjects studied. Our group and that of Lacy et al’s were 55yrs or older and we
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and others have recently demonstrated that AIx tends to plateau at around age 55yrs 
making it more difficult to demonstrate changes in AIx in this age group 90. However, 
CF PWV increases relatively little to age 55yrs and then rises steeply making it more 
likely that changes in CF PWV due to diabetes will be more easily distinguishable. 
Indeed, recent unpublished data from our own group support this hypothesis as 
diabetes induces little shift in the age AIx relationship under 55yrs but produces large 
shifts in the CF PWV age relationship in subjects over 55yrs (See Figure 1.9 in 
Chapter 1)
Study 2b: Comparison o f arterial stiffness in Caucasian type-2 diabetics and 
matched controls.
The previous study compared groups of type 2 diabetics and controls of mixed 
ethnicity. In this study Caucasian subjects with diabetes were compared to matched 
non diabetic Caucasian controls. Results were similar in that the diabetics had 
significantly higher CF PWV compared to control subjects with no significant 
differences in CR PWV. However, in contrast to the previous study there was a small 
but significant (P=0.04) difference in FD PWV with the diabetics exhibiting 
decreased FD PWV compared to the controls. This finding was unexpected and the 
reasons for it are very unclear since as discussed above most studies suggest that 
central arteries stiffen preferentially in subjects with diabetes. However, it does 
suggest that ethnic differences may exist in terms of FD PWV, in that, although no 
differences were seen in FD PWV when comparing mixed ethnicity groups of 
diabetics and controls there were differences in FD PWV within the Caucasian group. 
This issue could have been addressed by a comparison between South Asians with 
type 2 diabetes and matched South Asian controls. However, unfortunately this
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comparison was not possible due to the lack of older South Asian non diabetic 
controls making age matching impossible. In agreement with the first study in groups 
of diabetics and controls of mixed ethnicity the comparison between Caucasian 
diabetics and controls also showed no significant differences in AIx. As the age of the 
subjects was again 55yrs or over this may well be due to plateauing of the age AIx 
relationship at 55yrs as previously discussed above.
Study 2c: Comparison o f arterial stiffness in non-diabetic South Asians and 
Caucasians.
Despite South Asian residents in the UK having a similar incidence of ishaemic heart 
disease to Caucasians this group has a significantly lower rate of PVD 146,168. Since 
arterial stiffening may predispose to atherogenesis we hypothesised that an 
explanation for this interesting finding could be that South Asians had lower FD 
PWV than Caucasians thus providing some protection against the development of 
atheroma in this vascular bed. The findings of this study support this hypothesis and 
demonstrate for the first time ethnic differences in FD PWV. However, it was also 
observed that the South Asians also had significantly lower CF PWV than the 
Caucasians. Since the incidence of ischemic heart disease is similar between the two 
ethnic groups this finding is also somewhat unexpected. Interestingly, CR PWV was 
observed to be significantly higher in the South Asian group. Again, this finding is 
unexpected and may well be explained as a chance finding. More studies need to be 
conducted with much larger numbers to investigate this finding further.
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Study 2d: Comparison o f arterial stiffness in type-2 diabetics o f South Asian and 
Caucasian origin.
The study above compared indices of arterial stiffness in non diabetic South Asians 
and a group of matched Caucasians. In the final study we have now compared arterial 
stiffness in a group of South Asians with type 2 diabetes with age matched Caucasian 
diabetics. In contrast to the non-diabetics there were no significant differences 
between the groups. Interestingly, as mentioned earlier, in the presence of diabetes, 
rates of PVD and amputation are lower in South Asians than Caucasians. However, in 
this analysis I have illustrated that in the presence of diabetes, there was no 
significant difference in arterial stiffness observed in any of the vascular beds 
between the groups. These findings suggest that the development of diabetes has 
already caused an acceleration of the vascular ageing process associated with 
diabetes. Further studies are needed and could be addressed by comparing the 
relationship between age and PWV in the various vascular beds between ethnic 
groups. This is thus a limitation of the current study but would require very large 
numbers of subjects to complete. The current findings however may be of clinical 
importance in that early recognition of pre diabetic states such as metabolic syndrome 
may be especially important in subjects of South Asian origin. This is supported by 
findings in Chapter 5 that subjects with IFG already exhibit increased CF PWV 
compared to controls. The numbers in the study are relatively small and will need 
confirmation in larger studies.
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IMPAIRED FASTING GLUCOSE AND 
ARTERIAL STIFFNESS 
(STUDY 3)
5.1 Introduction
Diabetes mellitus is a major risk factor for cardiovascular morbidity and mortality. 
Whilst much of this increased risk may be due to clustering of traditional risk factors 
such as hypertension and dyslipidaemia, diabetes without other risk factors is still 
associated with increased cardiovascular risk compared to non-diabetic subjects 169. 
Increased arterial stiffness is an emerging independent risk factor for cardiovascular 
disease and thus may explain some of the unaccounted risk in subjects with diabetes. 
Indeed, diabetes has been shown to be associated with increased arterial stiffness (see 
Chapter 1, section 1.7.1). A number of studies have demonstrated a relationship 
between impaired glucose regulation and increased risk of mortality, CVD and 
development of type-2 diabetes. The DECODE study group in 1999, showed a 
positive relationship between mortality and impaired fasting glucose (IFG) in men and 
women (DECODE study). However, this was only observed when levels were above 
7mmol/l. However, the relationship between IFG and arterial stiffness remains 
unclear.
The Rotterdam Study has shown a positive association between IFG and arterial 
stiffness in 2,987 elderly normal subjects assessed by measurement of carotid arterial 
distensibility. However, this was only observed in subjects >75yrs 96. The Hoorn 
study also examined the association between abnormal glucose regulation and arterial 
stiffness in 1,193 subjects with diabetes, impaired glucose metabolism and
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normoglycaemia as assessed by PP and IMT in a variety of vascular beds. Although 
the investigators were able to demonstrate a positive relationship between impaired 
glucose metabolism and femoral and brachial IMT, they were unable to show a 
similar relationship for carotid IMT. Furthermore, the authors did not include a
0 7specific group with IFG in their analysis . Another study in older hypertensive non­
diabetic subjects showed no relationship between IFG and arterial stiffness assessed 
using pulse wave analysis. However, it was able to demonstrate a significant 
relationship between insulin resistance and arterial stiffness 103.
To date, few studies have examined the relationship between IFG and arterial stiffness 
with conflicting results. The largest of these studies (Tomiyama H et al 2006), has 
examined the relationship between IFG and increased arterial stiffness using PWV in 
2,080 Japanese men. Although the investigators were able to demonstrate a significant 
relationship between IFG and increased PWV, the results of this study are difficult to 
interpret, as the subjects were all hypertensive. Furthermore, the investigators used 
brachial-ankle PWV, which unlike CF PWV has not been shown to predict CV 
outcome . A similar study in only 282 Japanese, measured brachial-ankle PWV and 
demonstrated a positive relationship between PWV and IFG 101. Interestingly, the 
Rotterdam study investigated IFG and arterial stiffness, assessed by carotid artery 
distensibility, however, it only demonstrated a significant association in individuals 
over 75yrs %.The remaining studies, failed to show any association between IFG and 
arterial stiffness using CIMT I02, PWA 170. Furthermore, in a study which assessed the 
second derivative of plethysmogram as a measure of arterial stiffness, 2hr post 
challenge hyperglycaemia and not fasting glucose was associated with increased 
arterial stiffness104.
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This study therefore, examines the relationship between IFG and arterial stiffness 
using PWV and PWA, in 1,282 subjects divided into groups of normoglycaemia, IFG 
and type-2 diabetes.
Table 5.0. Im paired G lucose R egulation and A rterial Stiffness.
R eference Population, N M easurem ents M ain findings
Rotterdam Study 
[96]
2,987
normal subjects
Carotid artery 
distensibility
+’ve relationship 
between IFG and 
distensibility, only 
after 75years.
Hoorn Study [97] 1,193
normoglycaemic, 
impaired glucose 
metabolism or 
diabetes
Pulse Pressure and 
Catotid, Barchial 
and Femoral IMT.
Only brachial and 
femoral IMT was 
associated with 
impaired glucose 
metabolism group
Hoorn Study [98] 1,193
normoglycaemic, 
impaired glucose 
metabolism or 
diabetes
PWA (AIx) No difference in 
AIx between 
impaired glucose 
metabolism group 
and controls.
Cruickshank [33] 600 diabetic, 
impaired glucose 
tolerance or 
normoglycaemic. 
Longitudinal study 
over 10 years
aPWV Diabetic and IGT 
group were shown 
to correlate +’vely 
with a PWV and 
mortality.
Tomiyama [99] 2,080 Japanese 
hypertensive men. 
Normoglycaemic 
and impaired 
fasting glucose 
groups
BA PWV +’ve relationship 
between IFG and 
BA PWV
Ohnishi [101] 282 Japanese 
normals
BA PWV +’ve relationship 
between BA PWV 
and IFG
Hanefeld [102] Small study 
numbers
CIMT No association 
between CIMT and 
IFG
Sengstock [103] Small study 
numbers
PWA (AIx) No association 
between AIx and 
IFG
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5.2 Methodology
5.2.1 Subject Recruitment
Subjects were recruited from the open access metabolic syndrome risk factor clinic at 
the WHRI. In order to obtain a large cohort form the general population, individuals 
who attended our metabolic syndrome risk factor clinic were assessed. Word of mouth 
and various leaflets and handouts were distributed through various health days, 
ongoing around Cardiff also proved effective as a means of increasing the numbers 
attending the clinic. Advertisements in the South Wales Echo were also a helpful tool 
in increasing knowledge regarding the clinic. Individuals referred themselves to the 
clinic at times that was most suitable to them.
1,282 individuals aged 18-87years from Cardiff city and the surrounding area, were 
recruited for the study. A detailed personnel and family medical history questionnaire 
was completed by each individual. The study group comprised 1074 subjects with 
NFG (fasting blood glucose <5.6 mmol/L), 94 subjects with IFG (fasting blood 
glucose >5.6 and < 7.0 mmol/L) and 114 subjects with type-2 diabetes (fasting blood 
glucose >7.0 mmol/L). IFG and type-2 diabetes were defined according to ADA 
criteria. Ethical approval was obtained from the local research ethics committee. 
Informed consent was also obtained before any measurements were undertaken.
5.2.2 Data Collection
Participants entered the clinic as self-referrals from the general population. All 
individuals entered the clinic after a 12 hour overnight fast. The screening visit lasted 
approximately one hour. Informed consent was obtained before personnel and family
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medical history questionnaire was filled in. Participant’s height, weight, waist and hip 
circumference were all routinely measured.
5.2.3 Blood pressure Measurement
Blood pressure was recorded as described in Chapter 2, section 2.3.1.
5.2.4 Assessment o f Arterial Stiffness:
Pulse wave analysis and PWV were recorded using the SphygmoCor system as 
described in Chapter 2, section 2.3.2.1.1, section 2.3.2.1.2 and section 2.3.2.1.3.
5.2.5 Data Analysis and Statistics
These data were analysed using ANOVA and thereafter, a bonferroni corrected post 
hoc t- tests, with the statistics software package (SPSS, version 11.5, SPSS Inc., 
Chicago, Illinois) in order to compare means of each group. All values represent mean 
± SD, and a P value of < 0.05 was considered significant. When adjusting for certain 
parameters during the analysis. The slope of a linear regression model was used and 
each parameter adjusted accordingly.
In order to find the power of the test the thesis performed a power calculation to make 
sure the correct numberof subjects were recruited. See Chapter 2, section 2.4 for 
calculations
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5.3 Results
The three groups were matched for age. Tables 5.1 to 5.2 shows the differences 
between controls and subjects with IFG and type-2 diabetes, in terms of biochemical 
and metabolic parameters, along with seated and supine haemodynamic parameters. 
HBAlc was as expected raised in the type-2 diabetics compared to the 
normoglycaemic subjects and the subjects with IFG. Although HBAlc was higher in 
the IFG group compared to subjects with normogylcaemia this was not significant. 
TChol, LDL, HDL and TGs also differed between the groups. TChol was lower in the 
type 2 diabetics relative to the normoglycaemic group. LDL was significantly lower in 
both the IFG and diabetic group compared with the normoglycaemic subjects. HDL 
was only significantly lower in the IFG group compared with normogylcaemic 
controls. TGs were significantly higher in both the IFG and diabetic groups as 
expected. Interestingly no differences in CRP were observed between the groups.
As predicted, subjects with IFG and diabetes had significantly greater BMI weight 
and waist circumference than the normoglycaemic group. There were no significant 
differences in PMAP between any of the groups. Seated PPP was however 
significantly greater in the group with type-2 diabetes relative to the normoglycaemic 
group.
No significant differences were observed between groups in either the seated or 
supine positions.
CF PWV was significantly different between groups. Subjects with IFG having 
significantly higher CF PWV than normoglycaemic controls 9.4 ± 1.8 m/s versus 8.7 
± 1.8 m/s respectively (P<0.01). subjects with diabetes also exhibited a significantly
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greater CF PWV than the normoglycaemic group 9.9 ± 2.0 m/s versus 8.7 ± 1.8 m/s 
respectively (P<0.001, Figure 5.1). There were no significant differences in CF PWV 
between the IFG and diabetic groups. CR PWV was also assessed and no significant 
differences were observed between the three groups. AIx after correcting for height, 
MAP and heart rate was not significantly different between the groups (Table 5.1).
Fasting blood glucose levels for the whole cohort were plotted against CF PWV 
(Figure 5.2) and a significant relationship was observed (R2 = 0.023, PO.OOl). When 
the graph was spit in two, a significant relationship was only observed in the cohort 
with fasting blood glucose levels <7mmol/l (R2 = 0.022, PO.OOl). No relationship 
was observed in the diabetic group with fasting blood glucose levels > 7mmol/l (R2 = 
0.001, P= 0.83). See figure 5.3.
A multiple regression analysis with CF PWV as the dependant variable was also 
performed and showed that fasting glucose levels remained as predictive of CF PWV 
(Table 5.3).
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Table 5.1 Group characteristics and vascular haemodynamics, according to glucmetabolic classification.
N=
NFG
Mean ±SD 
1074
IFG
Mean ±SD 
94
DM
Mean ±SD 
114
P  Value
ANOVA
Grouo characteristics 
AGE (yrs) 53±19 54±18 56120 0.157
BMI (kg/m ) 26.0±4.3 27.5±5t 27.9i4.7f 0.000
HT (cm) 170±10 170±10 16819 0.056
WT (kg) 75±14 80±16f 79116* 0.001
WST CIRC. (cm) 87±13 95115T 96115f <0.001
AB CIRC. (cm) 91±16 96±11 95115 0.218
Vascular haemodvnamics (seated) 
PSBP (mmHg) 134±21 137117 138120 0.084
PDBP (mmHg) 81±11 82110 81111 0.732
PMAP (mmHg) 98±13 101113 99114 0.443
PPP (mmHg) 53±16 55114 57118* 0.025
CSBP (mmHg) 121±20 124118 123121 0.283
CDBP (mmHg) 82±11 83111 81112 0.547
CPP (mmHg) 39±15 41115 42117 0.147
AIX (%) 20.6±16 22.3116 19.6115 0.511
AIX (corrected) 17±15 18117 22115 0.495
HR (bpm) 69±12 71112 77115f# <0.001
AP (mmHg) 8.9±9 9.619 9.219 0.846
ED (ms) 299±27 297128 290+301| 0.009
TR (ms) 142±15 141119 137±13$ 0.008
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Groups vascular haemodynamics, according to glucometabolic classification, continued:
(supine)
NFG
Mean ±SD
IFG
Mean ±SD
DM
Mean ±SD
P  Value
ANOVA
PSBP (mmHg) 131±20 133±15 134120 0.250
PDBP (mmHg) 76±10 77±9 76110 0.504
PMAP (mmHg) 94±13 95±13 95114 0.804
PPP (mmHg) 55±15 56±12 58117 0.135
CSBP (mmHg) 119±20 120118 121121 0.497
CDBP (mmHg) 77±10 78110 76111 0.562
CPP (mmHg) 42±15 42112 45117 0.168
AIX (%) 22±17 22117 22116 0.986
AIX (corrected) 23±12 22110 24112 0.603
HR (bpm) 64±10 67111 71113f# <0.001
AP (mmHg) 10±10 9110 11110 0.598
TR (ms) 146±21 143119 141119 0.066
TR (corrected) 146±18 142117 142118 0.215
ED (ms) 327±23 318i25t 316i27f <0.001
CF PWV (m/s) 8.1±2.6 8.712.6* 9.513. OK# <0.001
CF PWV (corrected) 8.7±1.8 9.411.8f 9.9i2.0f <0.001
CR PWV (m/s) 8.1±1.4 8.111.4 8.311.4 0.502
CR PWV (corrected) 8.3±1.2 8.111.4 8.411.3 0.292
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Table 5.2 Biochemical profile, according to glucometabolic classification.
NFG
Mean ±SD
IFG
Mean ±SD
DM
Mean ±SD
P  Value
ANOVA
TCHOL (mmol/L) 5.1±1.1 4.911.0 4.711. I f <0.001
LDL (mmol/1) 3.06±0.97 2.8110.96* 2.5810.861 <0.001
HDL (mmol/1) 1.4510.43 1.37i0.47t 1.2910.55 0.001
TRIGS (mmol/1) 1.4310.92 1.8911.19T 1.9311.191 <0.001
GLUC (mmol/1) (fasting) 4.710.6 6.210.4T 8.413. l i f t <0.001
CRP (mg/l) 2.5614.32 3.4413.94 2.8513.37 0.395
HBAlc (%) 5.4510.42 5.6810.57 7.0211.771** <0.001
NFG: Normal fasting glucose. IFG: Impaired fasting glucose, DM: Diabetes mellitus, BMI: Body mass index, HT: Height, WT: Weight, 
WST CIRC: Waist circumference, AB CIRC: Abdominal circumference, PSBP: Peripheral systolic blood pressure, PDBP: Peripheral 
diastolic blood pressure, PMAP: Peripheral mean arterial pressure, PPP: Peripheral pulse Pressure, CSBP: Central systolic blood 
pressure, CDBP: Central diastolic blood pressure, CMAP: Central mean arterial pressure, CPP: Central pulse pressure, AIX: 
Augmentation index, A IX  (corrected): AIX corrected for height, peripheral mean arterial pressure and heart rate, AP: Augmentation 
pressure, HR: Heart rate, Tr: Time for the reflected wave to return, TR (corrected): Tr corrected for height, peripheral mean arterial 
pressure and heart rate, ED: Ejection duration, CF PWV: Carotid femoral pulse wave velocity, CF PW V (corrected): CF PWV 
corrected for age and peripheral mean arterial pressure, CR PWV: Carotid radial pulse wave velocity, CR PW V (corrected): CR PWV 
corrected for age and peripheral mean arterial pressure, TCHOL: Total cholesterol, LDL: Low density lipoprotein, HDL: High density 
lipoprotein, TRIGS: Triglycerides, GLUC: Glucose, CRP: C-reactiveprotein, H BAlc: GlycosolatedHaemoglobin.
* P<0.05, fP  <0.01, T P < 0.001 between NFT and IFG; $P<0.05, ||P <0.01, f  P < 0.001 between NFG and DM; # P<0.05, ** P <0.01,
t f P  < 0.001 between IFG and DM.
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Figure 5.1. The effect of fasting glucose levels on arterial stiffness.
P<0.01
ANOVA
P0.001
Normal Fasting Inpaired Fasting Dabetic 
Gucose Gucose
CF PWV (m/s): Carotid femoral pulse wave velocity, in metres per second.
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Table 5.3. Results of stepwise multiple regression analysis
Model r SE Beta P r2 Change (%)
AGE (yrs) 0.080 0.004 0.534 <0.001 44.6
PMAP (mmHg) 0.059 0.007 0.269 <0.001 6.8
GLUC (mmol/1) 0.191 0.054 0.095 <0.001 1.1
BMI (Kg/m2) 0.046 0.018 0.071 0.010 0.5
CF-PWV adjusted R2 = 0.529, P<0.001
PMAP: Peripheral mean arterial pressure, GLUC: Glucose, BMI: Body mass index, 
r: Regression coefficient.
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Figure 5.2. Scatterplot showing the relationship between CF PWV and fasting 
glucose levels in the whole cohort.
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Figure 5.3. Scatterplot showing the relationship between CF PWV and (a) fasting 
glucose levels <7.0mmol/l and (b) fasting glucose levels > 7.0 mmol/1.
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CF PWV (m/s): Carotid femoral pulse wave velocity, in metres per second.
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5.4 Discussion
A combination of classical risk factors (hypertension, obesity and dyslipidemia) may 
account for some but not all of the increased cardiovascular risk associated with type- 
2 diabetes 169. Increased arterial stiffness is an independent risk factor for CV disease 
and may mediate some of the increased risk associated with type-2 diabetes. The 
results of this study confirm previous findings that increased arterial stiffness is 
associated with type-2 diabetes and extend these findings to show that subjects with 
IFG also have increased arterial stiffness relative to normoglycaemic controls. 
Furthermore, a graded relationship was observed between normoglycaemia, IFG and 
type-2 diabetes. However, these data may be somewhat misleading as most diabetic 
individuals will have been on medication, which may influence arterial stiffness and 
mean arterial pressure. Therefore, a graph comparing CF PWV versus fasting glucose 
levels <7mmol/l (normoglycaemics and IFG group) and a graph comparing the effect 
of CF PW versus fasting glucose >7mmol/l (diabetics) were described. A graded 
relationship between fasting blood glucose and CF PWV was only observed in the 
group with fasting glucose levels <7mmol/l.
Other studies have shown increased arterial stiffness in the early stages of diabetes. 
However, unlike the current study this was defined as impaired glucose tolerance
7 ^ 171 1 77’ ’ . Few studies have been carried out comparing IFG and arterial stiffness. Of
these studies carried out, Tomiyama H et al, examined the relationship between IFG 
and increased arterial stiffness in 2,080 individuals. However, results of this study are 
difficult to interpret, as the subjects studied unlike the present study were all 
hypertensive, which could account for the increased arterial stiffness observed. 
Furthermore, the investigators used brachial-ankle PWV, which unlike CF PWV has
i nnnot been shown to predict CV outcome . The Rotterdam study also demonstrated an
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association between IFG and arterial stiffness, assessed using carotid artery
distensibility, however, this was only significant in individuals over 75yrs 96. Other
studies failed to show any association between IFG and arterial stiffness when
assessed using CIMT 102 and PWA 17°.
CF PWV was significantly higher in IFG group and DM group compared to the 
normal fasting glucose group. Interestingly, in agreement with other studies no 
significant differences were observed between the groups in terms of CR PWV, 
suggesting that increased glucose levels impact more on large elastic arteries such as 
the aorta rather than more muscular arteries such as the brachial. This may be due to 
the fact that diabetes predisposes to the development of collagen cross links in elastic 
tissue. This is supported by the fact that drugs that decrease collagen cross linking 
have been demonstrated to decrease CF PWV . As mentioned earlier, an increase in 
various other structural factors e.g. Matrix metalloproteinases (MMP-9), which are 
associated with increased large artery stiffness could also have been responsible for 
this observation. However, MMP-9 levels were not measured on this occasion. When 
the relationship between fasting glucose levels and CF PWV was assessed there was a 
significant relationship (PO.OOl).
AIx, a measure of wave reflection from the periphery was not different between the 
three groups. This in agreement with a previous study that also showed no difference 
in AIx between a group of diabetic patients and matched controls89. Like the current 
study the average age of the diabetics was 55 years. A possible explanation for these 
findings comes from our own data in a normal population showing that AIx tends to 
plateau at around age 55yrs, whilst CF PWV tends to rise more steeply after age
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55yrs. Thus, since the subjects in the current study were 55yrs it may be more difficult 
to show differences in AIx whereas, as was the case, differences in CF PWV would be 
more apparent. Support for this hypothesis comes from our own, as yet unpublished 
data, comparing changes in CF PWV and AIx with age in diabetic and normal 
subjects (Figure 1.9, Chapter 1). In subjects <55yrs there is a clear shift of the AIx 
curve to the left in diabetics relative to controls. Similarly the shift in the CF PWV 
curves occurs after the age of 55yrs (Figure 1.9, Chapter 1).
This increased arterial stiffness associated with IFG and type-2 diabetes, provides an 
interesting link relating diabetes to CVD. A number of studies have demonstrated 
endothelial dysfunction, characterised by a decreased bioavailability of endothelium 
derived nitric oxide (NO) and impaired glucose metabolism as possible mechanisms
1 7 1as to how the vasculature is affected since NO has been shown to regulate in part 
large arterial stiffness 65,66. Indeed, a recent study showed a relationship between 
endothelial function and CF PWV 174 in a normal population. Thus decreased 
bioavailability of NO may account for the increased arterial stiffness observed in 
subjects with IFG and diabetes. Furthermore, insulin has been shown to produce 
vasodilation in peripheral arterial beds via a NO dependent mechanism . However, the 
doses of insulin used in these experiments were non physiological. Recently insulin at 
physiological levels has been demonstrated to have an effect on arterial 
haemodynamics leading to decreased wave reflection 118176 and that these effects of 
insulin are similar to those of GTN 177 suggesting that NO may well be involved in the 
haemodynamic effects of insulin. Furthermore, these beneficial effects of insulin are 
blunted in subjects with insulin resistance 1I9. As yet, the haemodynamic effects of 
insulin have not been studied in non-diabetic subjects with endothelial dysfunction
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such as hypercholesterolaemia. Unfortunately, fasting insulin levels were not 
measured in this study, hence it is not possible to directly address this issue within the 
current cohort. However, data from the Caerphilly and Speedwell study have 
demonstrated that even though glucose concentrations were associated with ischaemic 
heart disease (IHD), fasting insulin concentrations were not shown to be associated 
with IHD178.
This study is limited to an observational design and without fasting insulin levels, we 
can only speculate as to the mechanisms involved. Further studies should look at 
fasting insulin levels as a surrogate measure for insulin resistance when performing 
studies similar to this. Furthermore, it would have been desirable to have more clinical 
data on all the individuals involved. Therefore, the influence of cardiovascular acting 
medications could be accounted for and analysed for clearer interpretation of the data. 
As mentioned earlier, data regarding the use of insulin, blood pressure medication, 
statins etc, could all have had an effect on the overall results. Unfortunately this data 
was not available and need for such data should be advised for future research in this 
area.
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EXERCISE AND ARTERIAL STIFFNESS 
(STUDY 4)
6.1 Introduction
171Lack of physical activity is an independent risk factor for CVD . Moreover, 
increased physical activity and physical fitness are associated with a decreased
1 7 0  15inincidence of CAD events ’ . The mechanisms whereby exercise reduces CV risk
are unclear but may involve improvement in cardiovascular risk factors such as
1 Q  1
hypertension, hyperglycaemia and hypercholesterolaemia . Indeed exercise has been
1 7 1shown to be very effective at reducing blood pressure . However, this may still not 
account for all the reduction in risk.
Recently increased arterial stiffness has emerged as an important independent CV risk 
factor and this has led a number of researchers to investigate the relationship between 
exercise and arterial stiffness. The results have been conflicting partly due to the 
populations studied and the methodologies employed to assess arterial stiffness. In 
addition exercise levels have been self-reported and there is a lack of prospective 
intervention studies on the effects of exercise. Furthermore, as previously stated 
exercise decreases blood pressure making it difficult to assess whether any observed 
beneficial changes in arterial stiffness are independent of reductions in MAP. Since 
arterial stiffening is an inevitable consequence of the ageing process, differences in 
ages between the populations studied may also account for some of the differing 
results reported. Finally, exercise may have differential effects on central and 
peripheral arteries.
The Northern Ireland Young Hearts Project (NIYHP) involving 405 young subjects 
(12-15yrs) demonstrated an inverse relationship between estimated cardio-respiratory
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fitness, and self-reported physical activity levels with arterial stiffness, assessed by
photoplethysmographic measurement of aorto-illiac and aorto-dorsalis pedis PWV 124.
However, the much larger ARIC study involving 10,644 older individuals free from
clinical evidence of CVD examined the relationship between physical activity and
arterial stiffness assessed using carotid intima media thickness (CIMT). Although the
study was able to show that people who performed vigorous physical activity had a
weekly positive association with arterial stiffness, there was no such relationship
between habitual physical activity and arterial stiffness . This study was cross
sectional and results from the longitudinal DANSCO study have shown that regular
low to moderate intensity aerobic exercise is associated with a 40% lower 6-year
1
progression of CIMT compared to a group taking little or no exercise . These 
findings are supported by a smaller study demonstrating that highly physically active 
women did not display the age related increases in aortic PWV that usually occur in 
elderly populations 133.
Results from intervention studies employing increased physical activity have also
1 #9been conflicting. In a small study of 17 Japanese middle aged men aerobic exercise 
of 16 weeks duration was shown to decrease central arterial stiffness, assessed by 
measuring aortic PWV. Interestingly, no effect was observed in the peripheral, more 
muscular arteries, of the femoral to dorsalis-pedis region. Suggesting a differential 
effect of exercise, according to the vascular bed studied. A further intervention in 555 
men and women showed that exercise in the form of graded walking, over a 24-month 
period, also decreased aortic PWV . A recent study examining the effect of exercise 
on brachial- ankle PWV showed that exercise prevented deterioration in arterial 
stiffness .
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These and other intervention studies may be confounded by the fact that exercise will 
improve a number of CV risk factors including blood glucose levels 135,183. Of 
particular relevance is the increase in insulin sensitivity and consequent improvement 
in fasting glucose levels associated with exercise 136. A number of studies have 
demonstrated that decreased physical inactivity is associated with adverse metabolic 
effects such as increased fasting glucose and raised triglycerides 137'139. Indeed, large 
population based studies have shown regular exercise to slow the onset on diabetes 
169. In Chapter 5, it has already been demonstrated that IFG is associated with 
increased arterial stiffness, which may be due to increased insulin resistance 
increasing arterial stiffness in part via a NO dependent mechanism.
Therefore, this study examined the relationship between regular exercise, arterial 
stiffness and fasting blood glucose levels in a large cohort of men and women with no 
clinical evidence of CV disease.
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Table 6.0. Exercise and Arterial Stiffness.
Exercise and Arterial Stiffness
Reference Population, N Measurements Main Findings
NIYHP [124] 405 young 
subjects (12-15 
years)
Photopleth. 
Aorto-iliac and 
aorto-dorsalis 
pedis PWV.
Inverse relationship between 
estimated CR fitness, PA 
levels and arterial stiffness
Kozakova
[125]
432 young -  
middle aged 
subjects
CIMT and 
carotid stiffness
Inverse correlation between 
habitual PA and both CIMT 
and carotid stiffness
Schmidt-
Trucksass
[128]
Small study 
numbers
Youngs elastic 
modulus.
LTPA was associated with 
decreased arterial stiffness
Vaitkevicius
[129]
146 men (54- 
75 years)
APWV and AIx Increased CR fitness is 
associated with decreased 
AIx and aPWV
Vaitkevicius
[129]
201 men 
(50years) 
Hypertensives, 
diabetics and 
smokers
AIx Increased CR fitness is 
associated with decreased 
AIx
DANSCO
[131]
140 middle aged 
men
CIMT Regular low to moderate 
intensity aerobic exercise is 
associated with a 40% lower 
6-year progression of CIMT 
compared to sedentary group
ACT Study 
[132]
555 men and 
women (35-75 
years)
aPWV Increased PA was associated 
with sig. decrease in aPWV 
after 24 mths walking 
intervention
Hayashi [182] 17 sedentary men PWV 16 weeks low -moderate PA 
is associated with a decrease 
in central arterial stiffness 
but not peripheral artery 
stiffness
Tanaka [133] 53 women aPWV Age related increases in 
arterial stiffness were not 
apparent in highly physically 
active women
ARIC [126] 10,644 older 
individuals
CIMT No relationship between 
habitual exercise and CIMT. 
A weak but +’ve relationship 
was observed with vigorous 
physical activity
Tanaka [127] Small study 
numbers
Carotid B mode 
ultrasound and 
applanation 
tonometry
Habitual physical activity 
did not exhibit any sig. 
difference in arterial 
stiffness compared to 
sedentary controls
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6.2 Methodology
6.2.1 Study population
Two hundred and fourteen healthy male volunteers, free from CV acting medication, 
aged 63±9 years, were recruited for this study.
Participants were classified as either sedentary (S) (defined as, partaking in absolutely 
no recreational physical activity whatsoever) or physically active (PA) (defined as, 
partaking in aerobic physical activity, at least three times a week, and for at least one 
hour duration). Subjects that participated in low to moderate physical activity or high 
resistance training were excluded from the study.
A detailed medical personal and family history questionnaire was completed. Subjects 
receiving cardiovascular medications were also excluded. Each participant filled in a 
detailed physical activity questionnaire, in order to strategically quantify levels of 
activity. Ethical approval was obtained form the local research ethics committee. 
Informed consent was also obtained before any measurements undertaken.
6.2.2 Blood Pressure Measurement
Blood pressure (BP) was recorded as discussed in chapter 2, section 2.3.1.
6.2.3 Pulse Wave Analysis
Pulse wave analysis and PWV were recorded using the SphygmoCor system as 
described in Chapter 2, section 2.3.2.1.1, section 2.3.2.1.2 and section 2.3.2.1.3.
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6.2.4 Biochemical Analyses
Biochemical parameters such as glucose, total cholesterol, LDL, HDL, triglycerides, 
sodium, potassium, creatinine, urea and C-reactive protein were all measured using 
standard biochemical procedures in the Heath Hospital, Cardiff.
6.2.5 Statistical Analysis
All data were analysed using SPSS (version 11.5.0) software for windows. Unpaired 
t-tests were used to determine differences between the two groups’ means. Results 
were expressed as mean±SD. A P-value of less than 0.05 was used to determine 
significance.
In order to find the power in this study, a power calculation was performed to ensure 
the correct number of subjects were recruited. See Chapter 2, section 2.4.
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6.3 Results
Haemodynamic parameters in seated and supine positions are shown in (Tables 6.1 
and 6.2). No significant differences were observed in MAP between the PA and S 
groups. CF PWV was significantly lower in the PA group compared to the S group 
(8.5±1.4 versus 9.1±2.0 m/s, P=0.035) respectively (Figure 6.1). Although AIx, after 
correction for height, MAP and heart rate was lower in the PA group this did not 
reach statistical significance.
Biochemical parameters are shown in (Table 6.3). As expected HDL cholesterol was 
significantly higher and TG’s lower in the PA group. Glucose levels were also 
significantly lower in the PA group (4.9±1.2 versus 5.6±2.1 mmol/L, P=0.029). 
Importantly there were no significant differences in total and LDL cholesterol 
between the groups.
Table 6.4. A multiple regression analysis was performed and illustrates that only age, 
glucose and BMI were the only factors responsible for CF PWV measurements 
recorded in this cohort (R2 = 0.26, P=0.031).
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Table 6.1 Differences in baseline characteristics in seated posture between 
sedentary and physically active elderly groups.
Sedentary
N=(214)
Active
N=(48) P  Value
Group Characteristics
Age (years) 64±8 61±14 NS
BMI (Kg/m2) 28±5 25±4 <0.001
Height (m) 167±8 167±9 NS
Vascular Haemodynamics (Seated)
PSBP (mmHg) 141±20 135±16 NS
PDBP (mmHg) 84±9 83±8 NS
PMAP (mmHg) 104±12 102±11 NS
PPP (mmHg) 56±16 52±12 NS
CSBP (mmHg) 131±19 125±16 0.022
CDBP (mmHg) 86±10 84±6 NS
CPP (mmHg) 45±14 41±12 0.22
AIx (%) 29±11 26±11 NS
HR (bpm) 72±10 69±13 NS
AP (mmHg) 14±8 11±7 NS
Tr (ms) 133±13 140±13 <0.001
ED (ms) 298±25 300±24 NS
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Table 6.2 Baseline characteristics in supine posture between sedentary and 
physically active elderly groups.
Sedentary
N=(214)
Active
N=(48) P  Value
Vascular Haemodynamics (Supine)
PSBP (mmHg) 130±17 132116 NS
PDBP (mmHg) 77±8 7918 NS
PMAP (mmHg) 95±10 97111 NS
PPP (mmHg) 54±14 53111 NS
CSBP (mmHg) 121±16 122117 NS
CDBP (mmHg) 78±8 8019 NS
CPP (mmHg) 44±13 43111 NS
AIx (%) 30±9 28112 NS
AIx (corrected) 34±8 30111 NS
HR (bpm) 67±10 64111 NS
AP (mmHg) 14±7 1317 NS
ED (ms) 324±23 328120 NS
Tr (ms) 136±13 141115 NS
Tr (corrected) 138±12 143112 0.02
CF PWV (m/s) 9.2±2.3 8.511.6 0.048
CFPWV (corrected) 9.1 ±2.0 8.511.4 0.035
CRPWV (m/s) 8.4±1.4 8.411.2 NS
CRPWV (corrected) 8.511.3 8.511.1 NS
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Table 6.3. Differences in biochemical profile observed between sedentary and 
physically active elderly groups.
Sedentary 
N= (170)
Active
N=(31) P  Value
TCHOL (mmol/1) 5.7±1.1 5.511.6 NS
LDL (mmol/1) 3.5±1.0 3.411.4 NS
HDL (mmol/1) 1.3510.4 1.710.5 0.003
TRIGS (mmol/1) 2.0±1.1 1.310.8 <0.001
GLUC (mmol/1) 5.612.1 4.911.2 0.029
NA (mmol/1) 14112.5 (N=53) 14112.5 NS
K (mmol/1) 4.410.4 (N=53) 4.410.4 NS
CREATININE (pmol/1) 77.6117 (N=53) 85115 0.045
UREA (mmol/1) 5.311.0 (N=53) 5.511.1 NS
CRP (mg/1) 4.213.9 (N=53) 4.9110.0 NS
TCHOL: Total cholesterol, LDL: Low density lipoprotein, HDL: High density 
lipoprotein, TRIGS: Triglycerides, GLUC: Glucose, NA: Sodium, K: Potassium, CRP: 
C-reactive protein. (N=): Illustrates the number o f measurements recorded for that 
group.
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Figure 6.1. Illustrates the differences observed in CF PWV between physically 
active and sedentary elderly groups.
AVG CF PWV (m/s)
* P<0.05
ACTIVE SEDENTARY
AVG  CF PWV (m/s); Average carotid to fem ora l pulse wave velocity, in metre per  
second.
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Table 6.4 Results of stepwise multiple regression analysis of the factors 
influencing CF PWV in this study.
Model r SE Beta P value r2 Change(%)
AGE (yrs) 0.084 0.020 0.390 <0.001 17.1
GLUC (mmol/l)0.304 0.132 0.219 0.024 5.0
BMI (Kg/m2) 0.090 0.041 0.206 0.031 4.2
CF PWV R2 = 0.263, P<0.001
GLUC: Fasting glucose levels, BMI: Body mass index, r: Regression coefficient.
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6.4 Discussion
This cross sectional study in 262 men and women demonstrates that CF PWV is 
significantly lower in the physically active (PA) group compared to sedentary (S) 
controls. The fact that there were no significant differences in blood pressure or heart 
rate between the PA and S groups suggest that only moderate increases in physical 
activity above sedentary are sufficient to produce changes in large arterial stiffness. In
150agreement with previous data there was no difference in CR PWV confirming that 
exercise may have differential effects on central elastic arteries compared to more 
muscular peripheral ones. This is supported by results from an intervention study 
which showed that 16-weeks of aerobic exercise decreased central aortic but not 
femoral-dorsalis pedis PWV 182. In addition fasting blood glucose levels were also 
found to be significantly lower in the PA group. The findings of the current study are 
not in agreement with data from much larger ARIC study. Although the ARIC study 
did show a positive association between vigorous physical exercise and CIMT, there 
was no such relationship between habitual physical activity and CIMT 126. However, a 
more recent study in a similar age group to the ARIC participants demonstrated an 
inverse relationship between habitual physical activity and the age dependent increase 
in carotid wall stiffness assessed by ultrasound 125. This is supported by data from 
another large study, which, like the current study assessed arterial stiffness by 
measuring PWV. Although this study assessed aorto-illiac PWV, in agreement with 
this data on CF PWV, it demonstrated a significant inverse relationship between 
aorto-illiac PWV and increased levels of physical activity 124
The present study is also consistent with results from a number of smaller studies 
which have shown that aerobic exercise training 182, increased PA levels 124,130,
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increased cardio respiratory fitness 129,184 and increased leisure time physical activity 
(LTPA) 128 to be associated with decreased arterial stiffness. Methods of measuring 
arterial stiffness in these studies included, B-mode ultrasound imaging, 
photoplethysmography, tissue doppler imaging and young’s elastic modulus and 
applanation tonometry.
Explanations for the effect of exercise on arterial stiffness remain unclear. There were 
no differences in MAP between the PA and S groups so that changes in blood 
pressure cannot be the explanation as to why the PA group exhibited a significantly 
lower CF PWV. Interestingly, when a multiple regression analysis was performed, 
only age, glucose levels and BMI were found to affect CF PWV results. See table 6.4. 
Other known factors that have previously been shown to be responsible for CF PWV 
were entered into the regression analysis but had little influence (Gender, Exercise, 
MAP, TCHOL, LDL, HDL and TRIGS). However, the study has very small numbers 
in the PA group to perform a reliable regression analysis. Therefore, more numbers 
are needed in order to identify the effect of exercise on CF PWV.
Furthermore, the PA group had a significantly lower fasting glucose relative to the S 
group. This may have been responsible for some of the effect of exercise on arterial 
stiffness. Indeed, studies in the previous chapter have shown that fasting glucose 
levels have a graded effect on arterial stiffness and that there is a weak but significant 
correlation between CF PWV and fasting glucose levels. Exercise may have direct or 
indirect effects on arterial stiffness. Since endothelium derived nitric oxide (NO) is, in 
part, involved in the regulation of arterial stiffness 65,66 changes in the bioavailability 
of NO could alter arterial stiffness. Indeed, exercise itself increases NO release from 
the vascular endothelium 185,186 and this increase in bioavailability of NO could then
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decrease arterial stiffness. Exercise may also indirectly influence arterial stiffness in 
that as in the current study it reduces fasting blood glucose levels 136. Increased blood 
glucose levels are associated with endothelial dysfunction and decreased 
bioavailability of nitric oxide NO and such effects are reversible on decreasing blood
1 87glucose . The decreased fasting blood glucose in the PA group may therefore also 
increase the bioavailability of NO and account for some of the decreased CF PWV 
seen in the PA group.
In addition exercise has been shown to decrease oxidative stress and levels of 
oxidized LDL (ox-LDL) 188 Since ox-LDL impairs endothelial function, decreased 
levels of ox-LDL may also increase levels of NO and reduce arterial stiffness.
Exercise improves insulin sensitivity and decreases insulin resistance. This also 
provides a possible explanation for the beneficial effects of exercise on arterial 
stiffness. Recently insulin at physiological levels has been demonstrated to have an 
effect on arterial haemodynamics leading to decreased wave reflection 118176 and that 
these effects of insulin are similar to those of GTN 177 suggesting that NO may well 
be involved in the haemodynamic effects of insulin. Furthermore, these beneficial 
effects of insulin are blunted in subjects with insulin resistance 119.
Finally since there is a relationship between arterial stiffening and atherosclerosis it is 
impossible to exclude the fact that habitual exercise may decrease atherogenesis 
(perhaps via NO mediated mechanisms) and thus a decrease in atheromatous 
deposition within the arterial wall may also contribute to reductions in structural 
arterial stiffness with exercise.
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There were no differences in AIx between the PA and S groups in the current study. 
This is in disagreement with a recent study by Binder et al. in men with no clinical 
evidence of CHD in which there was an inverse relationship between AIx measured, 
as in this study, using the SphymoCor system and cardio-respiratory fitness assessed
1 SOby VO2 max . However, this study, unlike the current one, included only men and 
more importantly the men were considerably younger than the men and women 
recruited in this study. The differences in age may provide an explanation for the 
different findings in that AIx has been shown to plateau with age especially beyond 
the age of 55yrs. Since the subjects in the current study were all > 60yrs of age 
differences in AIx may be more difficult to observe when comparing between groups. 
In contrast CF PWV changes little with age until after 55yrs and then rise steeply 
thereafter. It would have been interesting to see data on CF PWV in the study from 
Binder et al. However, this was not measured in that study. This is an important 
omission as it is CF PWV that has more evidence than AIx to support its predictive 
value for CV events100.
Many questions concerning the relationship between physical activity, arterial 
stiffness and CVD remain unanswered. Based on the current study and the results of 
others what is required is a large intervention study in subjects across a large age 
range with accurate haemodynamic measurements including assessment of arterial 
stiffness. Inclusion of measurements such as endothelial function, fasting insulin and 
glucose, CRP, ox-LDL would allow analyses to be conducted to study the relationship 
between the effect of exercise on these parameters and arterial stiffness in order to
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better understand how exercise improves arterial function. This will be discussed 
further in the final Chapter on future directions of research.
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FUTURE DIRECTIONS OF RESEARCH
7.1 Future directions of research
The past decade has seen an exponential rise in the incidence of diabetes, such that, by
the year 2025 it is estimated that over 50 people in every thousand will have diabetes.
This has important health implications as mortality rates for CAD are 2-4 times higher
in diabetics compared to healthy controls and overall life expectancy is reduced by 
10025% . Although non-diabetic women have less CHD than men the development of
diabetes increases a womans risk 5 times relative to a man191.
Furthermore, micro-vascular and macro-vascular complications in diabetics have 
considerable economic cost implications. The Code-2 study, conducted in 8 European 
countries, estimated that the health service costs of diabetes was 29 billion euros. This 
study also demonstrated that although routine management of diabetes accounted for 
50% of health service costs an estimated 50% came from preventable complications. 
Despite this very little is spent on interventions to prevent diabetes or slow its onset. 
Metabolic Syndrome is a pre -diabetic state and individuals with this condition have a 
4 times greater chance of developing type-2 diabetes, compared to someone who has 
not got the syndrome. A major component of the Metabolic Syndrome is impaired 
glucose tolerance. The current studies (Chapter 5) have shown that IFG is associated 
with increased arterial stiffness, itself an independent risk factor for CV events. 
Therefore, interventional studies are needed to assess the mechanisms relating arterial 
stiffness and IFG or the Metabolic Syndrome. However, the contributions of the 
various components of the metabolic syndrome to arterial stiffening remain unclear.
It is already well established that exercise is effective at slowing the progression to 
onset of diabetes in subjects at high risk of its development169. This thesis has also
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demonstrated a positive cross sectional relationship between increased physical 
activity and decreased arterial stiffness (Chapter 6). However, a number of important 
questions remain unanswered. Since exercise decreases a number of other CV risk 
factors such as hypertension and obesity, it is difficult to define the exact mechanisms 
responsible for the observed benefits of exercise on arterial stiffness and CV outcome. 
Furthermore, there are few studies examining the effect of exercise on IFG and 
arterial stiffness that are not confounded by the presence of additional risk factors.
Future studies should therefore be designed to assess the effect of exercise 
intervention and lifestyle changes on the individual components of the Metabolic 
Syndrome and their relationship to arterial stiffness. Furthermore, such studies should 
include male and female subjects across a wide age range and different ethnicities. 
Results from such studies should allow a better understanding of the factors regulating 
arterial stiffness and the influence of exercise on these factors. This would then allow 
a better understanding of the mechanisms contributing to the beneficial effects of 
exercise. Importantly longitudinal studies are needed to define the factors responsible 
for the progression of arterial stiffness. Such studies should incorporate detailed 
information on exercise including duration, intensity, regularity and type of exercise.
On the basis of the current findings, future studies need to take into consideration a 
study with a research programme of longitudinal design, over a number of years and 
assess the effect of an exercise intervention on pre-diabetes (IFG). The study should 
encompass a variety of ethnic groups around the Cardiff area, with the hope of 
gaining valuable data relating to the differences in vascular physiology. Large 
numbers will enable the investigator to assess the age related vascular changes
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specific to each ethnic group. This will follow on from the original results that have 
been presented in Chapter 4 (Study 2c and 2d).
When assessing the effects of exercise on arterial stiffness in diabetes and pre­
diabetes, the investigator should measure vascular haemodynamics parameters (Blood 
pressure (central and peripheral, seated and supine), pulse wave velocity (CR PWV, 
CF PWV, CD PWV and FD PWV) and pulse wave analysis (AIx, Tr, resting HR etc) 
using the SphygmoCor system) as part of the over all study design. Following the 
results of Chapter 3, the investigator accepts the good reproducibility of both systems 
in the measurement of arterial stiffness. However, the SphygmoCor system still 
remains the “gold standard” method of assessing CF PWV. Cardio respiratory fitness
a
(measured by VO max) should also be measured before the intervention is performed, 
as this is likely to change as a result of increased physical activity. Biochemical 
analysis will be performed similar to Chapters 5 and 6. However, Insulin levels should 
also be measured in order to predict insulin sensitivity.
A full personal medical history questionnaire should be completed and all medication 
detailed appropriately.
After baseline measurements and an exercise intervention of aerobic physical activity 
performed, subjects will return at 1, 2, 6, 12 and 24 months.
The large numbers recruited throughout the study will enable the investigator to 
perform a multiple regression analysis to determine the effect of exercise on arterial 
stiffness measurements. As mentioned earlier, without these large numbers, 
determination of the effect exercise alone has on arterial stiffness will be difficult to 
ascertain. Especially, as exercise is known to influence other confounding factors like 
cholesterol, glucose, insulin, heart rate, blood pressure, and waist circumference.
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A study along these lines will therefore help to elucidate the mechanisms responsible 
for arterial stiffening in diabetic, pre-diabetic and normoglycaemic subject groups 
derived from various ethnic populations.
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